



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12N	A2	(11) International Publication Number: WO 00/50563 (43) International Publication Date: 31 August 2000 (31.08.00)
<p>(21) International Application Number: PCT/US00/04416</p> <p>(22) International Filing Date: 22 February 2000 (22.02.00)</p> <p>(30) Priority Data: 60/121,651 24 February 1999 (24.02.99) US</p> <p>(71) Applicants (for all designated States except US): MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). MERCK FROSST CANADA & CO. [CA/CA]; 16711 Trans-canada Highway, Kirkland, Québec H9H 3L1 (CA). UNIVERSITY OF TORONTO [CA/CA]; Department of Pharmacology, 8 Taddle Road, Toronto, Ontario M1E 1B8 (CA).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): <u>HOWARD</u>, Andrew, D. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). <u>O'NEILL</u>, Gary, P. [CA/CA]; 16711 Trans-Canada Highway, Kirkland, Québec H9H 3L1 (CA). <u>O'DOWD</u>, Brian [CA/CA]; 8 Taddle Creek Road, Toronto, Québec M1E 1B8 (CA). <u>GEORGE</u>, Susan [CA/CA]; 8 Taddle Creek Road, Toronto, Ontario M1E 1B8 (CA).</p> <p>(74) Common Representative: MERCK & CO., INC.; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).</p>		<p>(81) Designated States: CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published Without international search report and to be republished upon receipt of that report.</p>
<p>(54) Title: G PROTEIN-COUPLED RECEPTOR RESEMBLING GALANIN RECEPTORS</p> <p>MHTVATSGPN ASWGAPANAS GCPGCGANAS DGPVPSPRAV DAWLVPLFFA ALMLLGLVGN 60</p> <p>SLVIYVICRH KPMRTVTNFI IANLAATDVT FLLCCVPFTA LLYPLPGWVL GDFMCKFVNY 120</p> <p>IQQVSQATC ATLTAMSVDR WYVTFPLRA LHRRTPLAL AVSLSIWVGS AAVSAPVLAL 180</p> <p>HRLSPGPRAY CSEAFPSRAL ERAFALYNLL ALYLLPLLAT CACYAAMLRH LGRVAVRPAP 240</p> <p>ADSALQGQVL AERAGAVRAK VSRLVAAVVL LFAACWGPIQ LFLVLQALGP AGSWHPRSYA 300</p> <p>AYALKTWAHC MSYSNSALNP LLYAFLGSHF RQAFRRVCPC APRRPRRPRR PGPSDPAAPH 360</p> <p>AELLRLGSHP APARAQKPGS SGLAARGLCV LGEDNAPL 398</p>		
<p>(57) Abstract</p> <p>Human and rat DNAs encoding a novel G-protein coupled receptor, GPR54, as well as proteins encoded by the DNAs, are provided. Methods of identifying agonists and antagonists of GPR54 are also provided.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LJ	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

TITLE OF THE INVENTION

G PROTEIN-COUPLED RECEPTOR RESEMBLING GALANIN RECEPTORS

CROSS-REFERENCE TO RELATED APPLICATIONS

5 Not applicable.

STATEMENT REGARDING FEDERALLY-SPONSORED R&D

Not applicable.

10 REFERENCE TO MICROFICHE APPENDIX

Not applicable.

FIELD OF THE INVENTION

15 This invention relates to novel human and rat DNAs encoding GPR54, a G protein-coupled receptor (GPCR) related to the galanin receptors, the proteins encoded by the DNAs, and methods of identifying selective agonists and antagonists of the proteins encoded by the DNAs.

BACKGROUND OF THE INVENTION

20 G-protein coupled receptors (GPCRs) are a very large class of membrane receptors that relay information from the exterior to the interior of cells. GPCRs function by interacting with a class of heterotrimeric proteins known as G-proteins. Most GPCRs function by a similar mechanism. Upon the binding of agonist, a GPCR catalyzes the dissociation of guanosine diphosphate (GDP) from the
25 α subunit of G proteins. This allows for the binding of guanosine triphosphate (GTP) to the α subunit, resulting in the disassociation of the α subunit from the β and γ subunits. The freed α subunit then interacts with other cellular components, and in the process passes on the extracellular signal represented by the presence of the agonist. Occasionally, it is the freed β and γ subunits which transduce the agonist
30 signal.

GPCRs possess common structural characteristics. They have seven hydrophobic domains, each about 20-30 amino acids long, linked by sequences of hydrophilic amino acids of varied length. These seven hydrophobic domains intercalate into the plasma membrane, giving rise to a protein with seven
35 transmembrane domains, an extracellular amino terminus, and an intracellular

carboxy terminus (Strader et al., 1994, Ann. Rev. Biochem. 63:101-132; Schertler et al., 1993, Nature 362:770-772l; Dohlman et al., 1991, Ann. Rev. Biochem. 60:653-688).

GPCRs are expressed in a wide variety of tissue types and respond to a wide range of ligands, *e.g.*, protein hormones, biogenic amines, peptides, lipid derived messengers, *etc.* Given their wide range of expression and ligands, it is not surprising that GPCRs are involved in many pathological states. This has led to great interest in developing modulators of GPCR activity that can be used pharmacologically. For example, Table 1 of Stadel et al., 1997, Trends Pharmacol. Sci. 18:430-437, lists 37 different marketed drugs that act upon GPCRs. Accordingly, there is a great need to understand GPCR function and to develop agents that can be used to modulate GPCR activity.

Galanin is widely distributed in the central and peripheral nervous system. Galanin in most species is a 29 amino acid peptide with an amidated carboxyl terminus. Human galanin is unique in that it is longer, 30 amino acids, and is not amidated. There is strong conservation of the galanin sequence, with the amino terminal fifteen residues being absolutely conserved in all species. Galanin immunoreactivity and binding is abundant in the hypothalamus, the locus coeruleus, the hippocampus, and the anterior pituitary, as well as regions of the spinal cord, the pancreas, and the gastrointestinal tract.

Injection of galanin into the paraventricular nucleus (PVN) of the hypothalamus produces a dose-dependent increase in feeding in satiated rats. Although galanin can enhance carbohydrate ingestion, studies have shown that it profoundly increases fat intake. It has been suggested that galanin shifts macronutrient preference from carbohydrate to fat. The same injections of galanin that increase feeding reduce energy expenditure and inhibit insulin secretion. There is enhanced galanin expression in the hypothalamus of genetically obese rats compared with their lean littermates. Injection of peptide galanin receptor antagonists into the PVN blocks the galanin-specific induction of increased fat intake. Specific galanin antisense oligonucleotides when injected into the PVN produce a specific decrease in galanin expression associated with a decrease in fat ingestion and total caloric intake while hardly affecting either protein or carbohydrate intake. Thus galanin appears to be a potential neurochemical marker related to the behavior of fat ingestion and galanin receptors are attractive targets for the development of drugs to treat obesity and other eating disorders.

Galanin inhibits cholinergic function and impairs working memory in rats. Lesions that destroy cholinergic neurons result in deficits in spatial learning tasks. While locally administered acetylcholine (ACh) reverses some of this deficit, galanin blocks this ACh-mediated improvement. Evidence from autopsy samples
5 from Alzheimer's disease-afflicted brains suggests an increased galinergic innervation of the nucleus basalis. Thus, if galinergic overactivity contributes to the decline in cognitive performance in Alzheimer's disease, galanin antagonists may be therapeutically useful in alleviating cognitive impairment.

Other physiological processes in which galanin has been implicated
10 include nociception (Verge et al., 1993, *Neurosci. Lett.* 149:193-197) and sexual behavior (Benelli et al., 1994, *Eur. J. Pharmacol.* 260:279-282).

In the rat, administration of galanin intracerebroventricularly, subcutaneously, or intravenously increases plasma growth hormone. Infusion of human galanin into healthy subjects also increases plasma growth hormone and
15 potentially enhances the growth hormone response to growth hormone releasing hormone (GHRH).

Galanin levels are particularly high in dorsal root ganglia. Sciatic nerve resection dramatically up-regulates galanin peptide and mRNA levels. Chronic administration of galanin receptor antagonists (M35, M15) after axotomy results in a
20 marked increase in self mutilation behavior in rats, generally considered to be a response to pain. Application of antisense oligonucleotides specific for galanin to the proximal end of a transected sciatic nerve suppressed the increase in galanin peptide levels with a parallel increase in autotomy. Galanin injected intrathecally acts synergistically with morphine to produce analgesia, this antinociceptive effect of
25 morphine is blocked by galanin receptor antagonists. Thus, galanin agonists may have some utility in relieving neural pain.

The actions of galanin are mediated by at least three high affinity galanin receptors that are coupled by pertussis toxin sensitive G_i/G_o proteins to inhibition of adenylate cyclase activity, closure of L-type Ca^{++} channels, and opening
30 of ATP-sensitive K^+ channels (Habert-Ortoli et al., 1994, *Proc. Natl. Acad. Sci. USA* 91:9780-9783; Howard et al., 1997, *FEBS Lett.* 405:285-290; Wang et al., 1997, *J. Biol. Chem.* 272:31949-31952; Kolakowski et al., 1998, *J. Neurochem* 71:2239-2251). Specific binding of ^{125}I -galanin (K_d approximately 1 nM) has been demonstrated in areas paralleling localization of galanin immunoreactivity:
35 hypothalamus, ventral hippocampus, basal forebrain, spinal cord, pancreas, and

pituitary. In most tissues, the amino terminus (GAL 1-15) is sufficient for high affinity receptor binding and agonist activity.

A galanin receptor cDNA was isolated by expression cloning from a human Bowes melanoma cell line. (Habert-Ortoli, et al. 1994. Proc. Nat. Acad. Sci., USA 91: 9780-9783). This receptor, GALR1, is expressed in human fetal brain and small intestine, but little else is known of its distribution. Gal(1-16) is at least 1,000 times more active than pGAL(3-29) as an inhibitor of ¹²⁵I-porcine galanin binding to this receptor transiently expressed in COS cells. It remains to be determined whether this receptor subtype represents the hypothalamic receptor that mediates galanin specific feeding behavior.

Galanin receptors have been described in several international patent publications (WO 98/03548; WO 97/46681; WO 97/26853; WO 98/29439; WO 98/29440; WO 98/29441; WO 95/22608). European Patent Application EP 711830 also describes a galanin receptor.

It would be desirable to identify additional galanin receptors so that they can be used to further characterize this biological system and to identify galanin receptor subtype selective agonists and antagonists.

SUMMARY OF THE INVENTION

The present invention is directed to novel human and rat DNAs that encode a G-protein coupled receptor, GPR54. The DNAs encoding GPR54 are substantially free from other nucleic acids and have the nucleotide sequences shown as SEQ.ID.NO.:1 (human GPR54) and SEQ.ID.NO.:2 (rat GPR54). Also provided are GPR54 proteins encoded by the novel DNA sequences. The GPR54 proteins are substantially free from other proteins and have the amino acid sequences shown as SEQ.ID.NO.:3 (human GPR54) and SEQ.ID.NO.:4 (rat GPR54). Methods of expressing GPR54 in recombinant systems and of identifying agonists and antagonists of GPR54 are provided.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1A-B shows the complete cDNA sequence and amino acid sequence of human GPR54. The DNA sequence shown is SEQ.ID.NO.:1. The amino acid sequence shown is SEQ.ID.NO.:3.

Figure 2A-B shows the complete cDNA sequence of rat GPR54 (SEQ.ID.NO.:2).

Figure 3 shows the complete amino acid sequence of human GPR54 (SEQ.ID.NO.:3).

Figure 4 shows the complete amino acid sequence of rat GPR54 (SEQ.ID.NO.:4).

5 Figure 5A-B shows the location of the rat GPR54 open reading frame. The nucleotide sequence shown is (SEQ.ID.NO.:2). The amino acid sequence shown is (SEQ.ID.NO.:4).

Figure 6 shows the results of a Northern blot of rat GPR54 mRNA in rat brain. Each lane contained 5 µg of poly(A)⁺ RNA isolated from various tissues.

10 Figure 7A-D shows darkfield autoradiograms of sagittal and coronal sections of rat brain showing the localization of GPR54 receptor mRNA. Figure 7A shows a lateral representative section at 0.9 mm. Also shown are representative sections at levels relative to the bregma at -3.3 mm (Figure 7B), -3.8 mm (Figure 7C), and -6.3 mm (Figure 7D). Aco = cortical nucleus of the amygdala; Ahv = anterior
15 hypothalamic area; Arc = hypothalamic arcuate nucleus; IC = inferior colliculus; CA, field of Ammon's horn; DG, dentate gyrus; DM, dorsomedial hypothalamic nucleus; LC, locus coeruleus; LH, lateral hypothalamic area, LHb, lateral habenular nucleus; MeA, medial nucleus of the amygdala; MPO, medial preoptic area; MRN, mesencephalic reticular nucleus; PAG, periaqueductal gray; PB, parabrachial nucleus;
20 PF, parafascicular thalamic nucleus; PH, posterior hypothalamic nucleus; PMV, ventral premammillary nucleus; PO, primary olfactory cortex; RSpl, retrosplenial cortex; SC, superior colliculus; SHy, septohypothalamic nucleus; VTA, ventral tegmental area; ZI, zona incerta.

Figure 8 shows an alignment of the amino acid sequence of rat GPR54 (SEQ.ID.NO.:4) with the amino acid sequence of rat GALR1 (SEQ.ID.NO.:5), rat GALR2 (SEQ.ID.NO.:6), rat GALR3 (SEQ.ID.NO.:7), and the rat opiod receptor DOR (SEQ.ID.NO.:8).

Figure 9 shows an alignment of the amino acid sequences of rat GPR54 (SEQ.ID.NO.:4) and human GPR54 (SEQ.ID.NO.:3).

30

DETAILED DESCRIPTION OF THE INVENTION

For the purposes of this invention:

"Substantially free from other proteins" means at least 90%, preferably 95%, more preferably 99%, and even more preferably 99.9%, free of other proteins.

35 Thus, a GPR54 protein preparation that is substantially free from other proteins will

contain, as a percent of its total protein, no more than 10%, preferably no more than 5%, more preferably no more than 1%, and even more preferably no more than 0.1%, of non-GPR54 proteins. Whether a given GPR54 protein preparation is substantially free from other proteins can be determined by such conventional techniques of assessing protein purity as, *e.g.*, sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) combined with appropriate detection methods, *e.g.*, silver staining or immunoblotting.

“Substantially free from other nucleic acids” means at least 90%, preferably 95%, more preferably 99%, and even more preferably 99.9%, free of other nucleic acids. Thus, a GPR54 DNA preparation that is substantially free from other nucleic acids will contain, as a percent of its total nucleic acid, no more than 10%, preferably no more than 5%, more preferably no more than 1%, and even more preferably no more than 0.1%, of non-GPR54 nucleic acids. Whether a given GPR54 DNA preparation is substantially free from other nucleic acids can be determined by such conventional techniques of assessing nucleic acid purity as, *e.g.*, agarose gel electrophoresis combined with appropriate staining methods, *e.g.*, ethidium bromide staining, or by sequencing.

“Functional equivalent” means a receptor which does not have exactly the same amino acid sequence as naturally occurring GPR54, due to alternative splicing, substitutions, deletions, mutations, or additions, but retains substantially the same biological activity as GPR54. Such functional equivalents will have significant amino acid sequence identity with naturally occurring GPR54. Genes and DNA encoding such functional equivalents can be detected by reduced stringency hybridization with a DNA sequence encoding naturally occurring GPR54. For the purposes of this invention, naturally occurring GPR54 has the amino acid shown as SEQ.ID.NO.:3 or SEQ.ID.NO.:4. A nucleic acid encoding a functional equivalent has at least about 50% identity at the nucleotide sequence level to SEQ.ID.NO.:1 or SEQ.ID.NO.:2.

A polypeptide has “substantially the same biological activity” as GPR54 if that polypeptide has a K_d for a ligand that is no more than 5-fold greater than the K_d of GPR54 having SEQ.ID.NO.:3 or SEQ.ID.NO.:4 for the same ligand. A polypeptide also has “substantially the same biological activity” as GPR54 if that polypeptide is capable of mediating the same functional response as naturally occurring GPR54 when exposed to the same ligand as naturally occurring GPR54. Examples of functional responses are: pigment aggregation in *Xenopus* melanophores,

changes in membrane currents in *Xenopus* oocytes, modulation of cAMP levels, changes in calcium concentration, changes in inositol phosphate levels, and coupling to inwardly rectifying potassium channels. One skilled in the art would be familiar with a variety of methods of measuring the functional responses of other G-protein coupled receptors and would be able to apply those methods to GPR54 (see, e.g., Lerner, 1994, Trends Neurosci. 17:142-146 [changes in pigment distribution in melanophore cells]; Yokomizo et al., 1997, Nature 387:620-624 [changes in cAMP or calcium concentration, chemotaxis]; Howard et al., 1996, Science 273:974-977 [changes in membrane currents in *Xenopus* oocytes]; McKee et al., 1997, Mol. Endocrinol. 11:415-423 [changes in calcium concentration measured using the aequorin assay]; Offermanns & Simon, 1995, J. Biol. Chem. 270:15175, 15180 [changes in inositol phosphate levels]). Zlokarnik et al., 1998, Science 279:84-88 and U.S. Patent No. 5,741,657 describe a reporter gene assay that can be adapted to measure GPR54 functional responses. The assay utilizes an inducible promoter-driven β -lactamase that cleaves a fluorescent substrate. Cleavage of the substrate leads to a change in fluorescence resonance energy transfer (FRET) between different portions of the substrate that is proportional to the magnitude of induction of the β -lactamase. Thus, the level of activation of the inducible promoter determines the amount of FRET measured. This level of induction of the promoter is in turn determined by the level of the substance (e.g., cAMP) the promoter is induced by. By choosing a promoter that is induced by a functional response that results from the interaction of a ligand and GPR54 (e.g., changes in cAMP levels), one can use this assay to measure GPR54 functional responses.

Depending upon the cells in which GPR54 is expressed, and thus the G-proteins with which GPR54 is coupled, certain of such methods as described above may be appropriate for measuring the functional responses of GPR54. It is well within the competence of one skilled in the art to select the appropriate method of measuring functional responses for a given experimental system.

A "conservative amino acid substitution" refers to the replacement of one amino acid residue by another, chemically similar, amino acid residue. Examples of such conservative substitutions are: substitution of one hydrophobic residue (isoleucine, leucine, valine, or methionine) for another; substitution of one polar residue for another polar residue of the same charge (e.g., arginine for lysine; glutamic acid for aspartic acid).

By "isolated GPR54 protein" or "isolated GPR54 DNA" is meant GPR54 protein or DNA encoding GPR54 that has been isolated from a natural source. Use of the term "isolated" indicates that GPR54 protein or DNA has been removed from its normal cellular environment. Thus, an isolated GPR54 protein may be in a

5 cell-free solution or placed in a different cellular environment from that in which it occurs naturally. The term isolated does not imply that an isolated GPR54 protein is the only protein present, but instead means that an isolated GPR54 protein is at least 95% free of non-amino acid material (*e.g.*, nucleic acids, lipids, carbohydrates) naturally associated with the GPR54 protein. Thus, a GPR54 protein that is expressed

10 in bacteria or even in eukaryotic cells which do not naturally (*i.e.*, without human intervention) express it through recombinant means is an "isolated GPR54 protein." Similarly, DNA encoding GPR54 that is present in bacteria or even in eukaryotic cells which do not naturally (*i.e.*, without human intervention) contain it through recombinant means is an "isolated DNA encoding GPR54."

15 The present invention pertains to the discovery of DNA encoding a galanin receptor-like protein. Two degenerate primers (P1 and P2, see Example 1) based on conserved GPCR sequences in transmembrane segment 3 (TM3) and transmembrane segment 7 (TM7), respectively, were used to amplify an aliquot of a rat brain cDNA library with proof-reading *Pfu* polymerase. The amplified DNA was

20 excised and subcloned into the pBluescript vector. One of the resulting rat clones appeared to partially encode a galanin/opioid-like receptor. The partial cDNA was labeled with ^{32}P dCTP- α and used to screen the cDNA library employed in the degenerate PCR. Two positive plaques were purified and their inserts amplified by PCR using *Pfu* polymerase and primers flanking the cloning site of the $\lambda\text{gt}11$ vector.

25 The PCR products were subcloned into pBluescript and sequenced. Sequence analysis revealed that each plaque encoded a region of a putative GPCR from TM3 to the carboxy terminus identical to each other and the original probe. A second round of screening of 1×10^6 plaques freshly plated from the same library yielded an additional three positive plaques. PCR amplification of these positive plaques with

30 $\lambda\text{gt}11$ flanking primers, each paired with an internal primer, revealed that only one of these positive plaques contained the entire open reading frame (ORF). This plaque was purified, the insert subcloned into pBluescript and was confirmed to contain the 5' end of the full-length open reading frame. Finally, two specific primers from the 5' and 3' ends of the ORF were used to amplify with *pfu* polymerase the full length rat

cDNA 1.2 Kb clone, named GPR54. Sequence analysis revealed the cloned GPR54 ORF to be identical to the previous phage clones and the original probe.

GPR54 contained an ORF of 1,185 bp encoding a protein of 395 amino acids.

5 Using GPR54 in a BLAST search (Altschul, 1997, Nucleic Acids Res 25:3389-3402), the highest identity was observed with the galanin and opioid receptor families. Specifically, GPR54 shared an amino acid sequence identity in the TM regions with rat galanin receptors GalR1(45%), GalR3 (45%), GalR2 (44%), and rat opioid receptor DOR (37%) (Figure 8). Conserved residues and consensus sequences
10 of the rhodopsin superfamily of GPCRs present in GPR54 included an asparagine in TM1, an aspartate in TM2, prolines in TMs 4 through 7, three consensus sequences for N-linked glycosylation in the amino terminus, cysteines in the first and second extracellular loops, a PKA/PKC consensus sequence in the second intracellular loop, a PKC consensus sequence in the third intracellular loop, and three possible
15 palmitoylation cysteine sites in the carboxy tail. Significantly, various residues in the human GalR1 receptor shown to be important for high-affinity galanin binding (corresponding to His262, His265, Glu269, and Phe280 in rat GalR1; (Kask et al., 1996, EMBO J. 15:236-244 (Kask); Berthold et al., 1997, Eur. J. Biochem. 249:601-606 (Berthold)) were not conserved in GPR54. Among these however, only His262 is
20 conserved among the three galanin receptors. In addition, the substitution of a tyrosine residue found in GPR54, GalR2 and GalR3 in place of Phe280 in GalR1 was shown to have no significant effect on galanin binding (Kask) as opposed to previous studies where Phe280 was replaced by alanine in GalR1 (Berthold).

Both Northern blot and *in situ* hybridization analyses of GPR54 were
25 performed at high stringencies and with a DNA probe encoding GPR54 from TM3 to TM7 and with low identities to the genes encoding galanin and related receptors. The tissue distribution of GPR54 was obtained by northern blot analysis using poly(A)⁺ RNA isolated from various rat tissues (Figure 6). In the brain, multiple RNA transcripts with a complex pattern were detected in the medulla pons, midbrain,
30 hippocampus, cortex, frontal cortex, and striatum. The most intense band was approximately 3.7 Kb in length, with a single, larger transcript of approximately 12 Kb length detected in the liver and intestine only. No transcripts were revealed in the cerebellum or kidney tissues.

Using *in situ* hybridization of rat brain sections, the distribution of
35 GPR54 mRNA was found to be discretely localized to many areas (Figure 7). The

highest levels of expression were seen in hypothalamic and amygdaloid nuclei. GPR54 mRNA was highly expressed in the zona incerta, ventral tegmental area, dentate gyrus, hypothalamic arcuate nucleus, dorsomedial hypothalamic nucleus, primary olfactory cortex, lateral habenular nucleus, lateral hypothalamic area, locus coeruleus, and the cortical and medial nuclei of the amygdala. GPR54 mRNA was also concentrated in the superior colliculus, medial preoptic area, anterior hypothalamic area, posterior hypothalamic nucleus, periaqueductal gray, parafascicular thalamic nucleus, parabrachial nucleus, and ventral premammillary nucleus. The signals detected in the septohypothalamic nucleus, inferior colliculus, medial nucleus of the amygdala, mesencephalic reticular nucleus and retrosplenial cortex were diffuse and less abundant.

GPR54's CNS expression pattern was found to resemble those of galanin receptors. Specifically, rat GalR1 mRNA expression is abundant in several brain regions including the hypothalamus, amygdala, hippocampus and locus coeruleus (Parker et al., 1995, *Mol. Brain Res.* 34:179-189). Rat GalR2 mRNA expression is found in the mammillary nuclei, the dentate gyrus and posterior hypothalamic and arcuate nuclei (Kolakowski et al., 1998, *J. Neurochem.* 71, 2239-2251). Rat GalR3 is found to be abundantly expressed in the CA regions of Ammon's horn and the dentate gyrus with transcripts also detected in thalamic, hypothalamic, mammillary and amygdaloid nuclei (Kolakowski et al., 1998, *J. Neurochem.* 71, 2239-2251).

The identity and overlapping expression patterns of GPR54 with the galanin receptors suggested that the encoded receptor may demonstrate binding to galanin. In preparation for expression and binding studies, the 1.2 kb cDNA fragment encoding the ORF of GPR54 was subcloned into the multiple cloning site of the pcDNA3 expression vector and transiently transfected into COS-7 cells. No specific binding was observed with ¹²⁵I-human galanin. In contrast, specific and high affinity binding was observed under similar conditions with ¹²⁵I-human galanin in membranes prepared from COS cells transfected with human GalR1, consistent with a previous report for GalR2 and GalR3 (Kolakowski et al., 1998, *J. Neurochem.* 71, 2239-2251).

A BLAST search with the rat GPR54 sequence revealed high identity with a human 3.5 Mb contig located in chromosome 19p13.3 containing a serine protease gene cluster (GenBank accession number AC005379). Sequence analysis revealed a previously unrecognized 3.3 kb intron-containing human orthologue of

GPR54 encoding a protein 398 amino acids in length and sharing a translated amino acid identity of 81% (100% identity in the TM regions) with rat GPR54. The genomic sequence revealed four introns located in TM2 (~800 bp, interrupting the translated FYL..ANL sequence), TM3 (~800 bp, interrupting IQQ..VSV), TM4 (~250 bp, interrupting WVG..SAA) and in the third intracellular loop (~180 bp, interrupting ALQ..GQV).

One aspect of this invention is an isolated DNA comprising nucleotides encoding a polypeptide having the amino acid sequence SEQ.ID.NO.:3 or SEQ.ID.NO.:4. This isolated DNA can be substantially free from other nucleic acids and can be either single stranded or double stranded, *i.e.*, paired with its complementary sequence. Also within the present invention is isolated RNA corresponding to this DNA.

Another aspect of this invention is the identification and cloning of a cDNA which encodes GPR54, a G protein-coupled receptor. This cDNA is substantially free from other nucleic acids and can be either single stranded or double stranded. The present invention provides a cDNA molecule substantially free from other nucleic acids having the nucleotide sequence shown in Figure 1 as SEQ.ID.NO.:1 or in Figure 2 as SEQ.ID.NO.:2. SEQ.ID.NO.:1 contains an open reading frame (positions 1-1,194 of SEQ.ID.NO.:1) encoding a protein of 398 amino acids. SEQ.ID.NO.:2 contains an open reading frame (positions 61-1,245 of SEQ.ID.NO.:2) encoding a protein of 395 amino acids. (see Figure 5A-B).

Thus, the present invention also provides a DNA molecule substantially free from other nucleic acids comprising the nucleotide sequence of positions 1-1,194 of SEQ.ID.NO.:1 as well as a DNA molecule substantially free from other nucleic acids comprising the nucleotide sequence of positions 61-1,245 of SEQ.ID.NO.:2. The present invention also provides recombinant DNA molecules comprising the nucleotide sequence of positions 1-1,194 of SEQ.ID.NO.:1 or positions 61-1,245 of SEQ.ID.NO.:2.

Based on their predicted amino acid sequences, the human and rat GPR54 proteins most likely represent novel G-protein coupled receptors (GPCRs) since these GPR54 proteins obtain many of the characteristic features of GPCRs, *e.g.*,

- (a) seven transmembrane domains;
- (b) three intracellular loops;
- (c) three extracellular loops; and
- (d) the GPCR triplet signature sequence.

Northern blot and *in situ* hybridization analyses such as Figure 6 and Figure 7 showed that GPR54 RNA is widely expressed in rat brain regions (pons, midbrain, thalamus, hypothalamus, hippocampus, amygdala, cortex, frontal cortex, and striatum) as well as peripheral regions (liver and intestine).

5 The novel DNA sequences of the present invention encoding GPR54, in whole or in part, can be linked with other DNA sequences, *i.e.*, DNA sequences to which GPR54 is not naturally linked, to form "recombinant DNA molecules" containing GPR54 sequences. The novel DNA sequences of the present invention can be inserted into vectors in order to direct recombinant expression of GPR54. Such
10 vectors may be comprised of DNA or RNA; for most purposes DNA vectors are preferred. Typical vectors include plasmids, modified viruses, bacteriophage, cosmids, yeast artificial chromosomes, and other forms of episomal or integrated DNA that can encode GPR54. One skilled in the art can readily determine an appropriate vector for a particular use.

15 Included in the present invention are DNA sequences that hybridize to SEQ.ID.NO.:1 or SEQ.ID.NO.:2 under stringent conditions. By way of example, and not limitation, a procedure using conditions of high stringency is as follows: Prehybridization of filters containing DNA is carried out for 2 hr. to overnight at 65°C in buffer composed of 6X SSC, 5X Denhardt's solution, and 100 µg/ml denatured
20 salmon sperm DNA. Filters are hybridized for 12 to 48 hrs at 65°C in prehybridization mixture containing 100 µg/ml denatured salmon sperm DNA and 5-20 X 10⁶ cpm of ³²P-labeled probe. Washing of filters is done at 37°C for 1 hr in a solution containing 2X SSC, 0.1% SDS. This is followed by a wash in 0.1X SSC, 0.1% SDS at 50°C for 45 min. before autoradiography.

25 Other procedures using conditions of high stringency would include either a hybridization step carried out in 5XSSC, 5X Denhardt's solution, 50% formamide at 42°C for 12 to 48 hours or a washing step carried out in 0.2X SSPE, 0.2% SDS at 65°C for 30 to 60 minutes.

30 Reagents mentioned in the foregoing procedures for carrying out high stringency hybridization are well known in the art. Details of the composition of these reagents can be found in, *e.g.*, Sambrook, Fritsch, and Maniatis, 1989, Molecular Cloning: A Laboratory Manual, second edition, Cold Spring Harbor Laboratory Press. In addition to the foregoing, other conditions of high stringency which may be used are well known in the art.

The degeneracy of the genetic code is such that, for all but two amino acids, more than a single codon encodes a particular amino acid. This allows for the construction of synthetic DNA that encodes the GPR54 protein where the nucleotide sequence of the synthetic DNA differs significantly from the nucleotide sequence of SEQ.ID.NO.:1 or SEQ.ID.NO.:2, but still encodes the same GPR54 protein as SEQ.ID.NO.:1 or SEQ.ID.NO.:2. Such synthetic DNAs are intended to be within the scope of the present invention. If it is desired to express such synthetic DNAs in a particular host cell or organism, the codon usage of such synthetic DNAs can be adjusted to reflect the codon usage of that particular host cell or organism, thus leading to higher levels of expression of GPR54 protein in the host.

Another aspect of the present invention includes host cells that have been engineered to contain and/or express DNA sequences encoding GPR54. Such recombinant host cells can be cultured under suitable conditions to produce GPR54. An expression vector containing DNA encoding GPR54 can be used for expression of GPR54 in a recombinant host cell. Recombinant host cells may be prokaryotic or eukaryotic, including but not limited to, bacteria such as *E. coli*, fungal cells such as yeast, mammalian cells including, but not limited to, cell lines of human, bovine, porcine, monkey, and rodent origin, and insect cells including but not limited to, *Drosophila* and silkworm derived cell lines. Cell lines derived from mammalian species which are suitable for recombinant expression of GPR54 and which are commercially available, include but are not limited to, L cells L-M(TK⁻) (ATCC CCL 1.3), L cells L-M (ATCC CCL 1.2), HEK 293 (ATCC CRL 1573), Raji (ATCC CCL 86), CV-1 (ATCC CCL 70), COS-1 (ATCC CRL 1650), COS-7 (ATCC CRL 1651), CHO-K1 (ATCC CCL 61), 3T3 (ATCC CCL 92), NIH/3T3 (ATCC CRL 1658), HeLa (ATCC CCL 2), C127I (ATCC CRL 1616), BS-C-1 (ATCC CCL 26), MRC-5 (ATCC CCL 171), *Xenopus* melanophores, and *Xenopus* oocytes.

Human embryonic kidney (HEK 293) cells and Chinese hamster ovary (CHO) cells are particularly suitable for expression of the GPR54 protein because these cells express a large number of G-proteins. Thus, it is likely that at least one of these G-proteins will be able to functionally couple the signal generated by interaction of GPR54 and its ligands, thus transmitting this signal to downstream effectors, eventually resulting in a measurable change in some assayable component, *e.g.*, cAMP level, expression of a reporter gene, hydrolysis of inositol lipids, or intracellular Ca²⁺ levels.

Other cells that are particularly suitable for expression of the GPR54 protein are immortalized melanophore pigment cells from *Xenopus laevis*. Such melanophore pigment cells can be used for functional assays using recombinant expression of GPR54 in a manner similar to the use of such melanophore pigment cells for the functional assay of other recombinant GPCRs (Graminski et al., 1993, J. Biol. Chem. 268:5957-5964; Lerner, 1994, Trends Neurosci. 17:142-146; Potenza & Lerner, 1992, Pigment Cell Res. 5:372-378).

A variety of mammalian expression vectors can be used to express recombinant GPR54 in mammalian and other cells. Commercially available mammalian expression vectors which are suitable include, but are not limited to, pCR2.1 (Invitrogen), pMC1neo (Stratagene), pSG5 (Stratagene), pcDNAI and pcDNAIamp, pcDNA3, pcDNA3.1, pCR3.1 (Invitrogen), EBO-pSV2-neo (ATCC 37593), pBPV-1(8-2) (ATCC 37110), pdBPV-MMTneo(342-12) (ATCC 37224), pRSVgpt (ATCC 37199), pRSVneo (ATCC 37198), and pSV2-dhfr (ATCC 37146). For expression in non-mammalian cells, various suitable expression vectors are known in the art. The choice of vector will depend upon cell type used, level of expression desired, and the like. Following expression in recombinant cells, GPR54 can be purified to a level that is substantially free from other proteins by conventional techniques, e.g., salt fractionation, ion exchange chromatography, size exclusion chromatography, hydroxylapatite adsorption chromatography, hydrophobic interaction chromatography, and preparative gel electrophoresis.

The present invention includes GPR54 protein substantially free from other proteins. The amino acid sequence of the full-length human GPR54 protein is shown in Figure 3 as SEQ.ID.NO.:3. The amino acid sequence of the full-length rat GPR54 protein is shown in Figure 4 as SEQ.ID.NO.:4. Thus, the present invention includes GPR54 proteins substantially free from other proteins having the amino acid sequence of SEQ.ID.NO.:3 or SEQ.ID.NO.:4.

As with many receptor proteins, it is possible to modify many of the amino acids of GPR54, particularly those which are not found in the ligand binding domain, and still retain substantially the same biological activity as the original receptor. Thus, the present invention includes modified GPR54 polypeptides which have amino acid deletions, additions, or substitutions but that still retain substantially the same biological activity as naturally occurring GPR54. It is generally accepted that single amino acid substitutions do not usually alter the biological activity of a protein (see, e.g., Molecular Biology of the Gene, Watson et al., 1987, Fourth Ed.,

The Benjamin/Cummings Publishing Co., Inc., page 226; and Cunningham & Wells, 1989, Science 244:1081-1085). Accordingly, the present invention includes polypeptides where one amino acid substitution has been made in SEQ.ID.NO.:3 or SEQ.ID.NO.:4 wherein the polypeptides still retain substantially the same biological activity as naturally occurring GPR54. The present invention also includes polypeptides where two or more amino acid substitutions have been made in SEQ.ID.NO.:3 or SEQ.ID.NO.:4 wherein the polypeptides still retain substantially the same biological activity as naturally occurring GPR54. In particular, the present invention includes embodiments where the above-described substitutions are conservative substitutions. In particular, the present invention includes embodiments where the above-described substitutions do not occur in the ligand-binding domain of GPR54.

When deciding which amino acid residues of GPR54 may be substituted to produce polypeptides that are functional equivalents of GPR54, one skilled in the art would be guided by a comparison of the amino acid sequence of GPR54 with the amino acid sequences of related proteins, *e.g.*, the human, mouse, or rat GALR1, GALR2, or GALR3 receptors, as well as the rat opiod receptor DOR (see, *e.g.*, Figure 8). Such a comparison would allow one skilled in the art to minimize the number of amino acid substitutions made in regions that are highly conserved between GPR54 and the related proteins. Accordingly, the present invention includes polypeptides where two or more amino acid substitutions have been made in SEQ.ID.NO.:3 or SEQ.ID.NO.:4 where the polypeptides still retain substantially the same biological activity as naturally occurring GPR54 and where the substitutions are conservative and do not occur in positions where GPR54 and any of the human, mouse, or rat GALR1, GALR2, or GALR3 receptors share the same amino acid, or do not occur in positions where GPR54 and the rat opiod DOR receptor share the same amino acid (see Figure 8). In particular embodiments, the substitutions do not occur in positions where GPR54 and any of the rat GALR1, GALR2, or GALR3 receptors share the same amino acid (see Figure 8).

One skilled in the art would also recognize that polypeptides that are functional equivalents of GPR54 and have changes from the GPR54 amino acid sequence that are small deletions or insertions of amino acids could also be produced by following the same guidelines, *i.e.*, minimizing the differences in amino acid sequence between GPR54 and related proteins. Small deletions or insertions are generally in the range of about 1 to 5 amino acids. The effect of such small deletions

or insertions on the biological activity of the modified GPR54 polypeptide can easily be assayed by producing the polypeptide synthetically or by making the required changes in DNA encoding GPR54 and then expressing the DNA recombinantly and assaying the protein produced synthetically or by such recombinant expression.

- 5 Assays that could be used include simple binding assays to determine if the modified GPR54 polypeptide is capable of binding the same ligands, with approximately the same affinity, as naturally occurring GPR54 protein. Alternatively, one can use functional assays such as assays such as those described herein.

- 10 The present invention also includes C-terminal truncated forms of GPR54, particularly those which encompass the extracellular portion of the receptor, but lack the intracellular signaling portion of the receptor. Such truncated receptors are useful in various binding assays described herein, for crystallization studies, and for structure-activity-relationship studies.

- 15 The present invention also includes chimeric GPR54 proteins. Chimeric GPR54 proteins consist of a contiguous polypeptide sequence of GPR54 fused in frame to a polypeptide sequence of a non-GPR54 protein. For example, the N-terminal domain and seven transmembrane spanning domains of GPR54 fused at the C-terminus in frame to a G protein would be a chimeric GPR54 protein.

- 20 The present invention also includes GPR54 proteins that are in the form of multimeric structures, *e.g.*, dimers. Such multimers of other G-protein coupled receptors are known (Hebert *et al.*, 1996, J. Biol. Chem. 271, 16384-16392; Ng *et al.*, 1996, Biochem. Biophys. Res. Comm. 227, 200-204; Romano *et al.*, 1996, J. Biol. Chem. 271, 28612-28616). The dimers may be homodimers containing two GPR54 proteins or the dimers may be heterodimers containing GPR54 and another
25 protein.

The present invention also includes isolated forms of GPR54 proteins.

- 30 The present invention includes methods of identifying compounds that specifically bind to GPR54 protein, as well as compounds identified by such methods. The specificity of binding of compounds having affinity for GPR54 is shown by measuring the affinity of the compounds for recombinant cells expressing the cloned receptor or for membranes from such cells. Expression of the cloned receptor and screening for compounds that bind to GPR54, or that inhibit the binding of a known ligand of GPR54 to such cells, or membranes prepared from such cells, provides an effective method for the rapid selection of compounds with high affinity for GPR54.
35 Such ligands or compounds can be radiolabeled, but can also be nonisotopic

compounds that can be used to displace bound radiolabeled ligands or that can be used as activators or inhibitors in functional assays. Compounds identified by the above method are likely to be agonists or antagonists of GPR54 and may be peptides, proteins, or non-proteinaceous organic molecules. Such compounds are likely to be pharmacologically useful modulators of GPR54 activity.

Therefore, the present invention includes assays by which GPR54 agonists and antagonists may be identified. Methods for identifying agonists and antagonists of other receptors are well known in the art and can be adapted to identify agonists and antagonists of GPR54. Accordingly, the present invention includes a method for determining whether a substance is a potential agonist or antagonist of GPR54 that comprises:

- (a) transfecting cells with an expression vector encoding GPR54;
 - (b) allowing the transfected cells to grow for a time sufficient to allow GPR54 to be expressed;
 - (c) exposing the cells to a labeled ligand of GPR54 in the presence and in the absence of the substance;
 - (d) measuring the binding of the labeled ligand to GPR54;
- where if the amount of binding of the labeled ligand is less in the presence of the substance than in the absence of the substance, then the substance is a potential agonist or antagonist of GPR54.

The conditions under which step (c) of the method is practiced are conditions that are typically used in the art for the study of protein-ligand interactions: *e.g.*, physiological pH; salt conditions such as those represented by such commonly used buffers as PBS or in tissue culture media; a temperature of about 4°C to about 55°C.

The present invention also includes a method for determining whether a substance is capable of binding to GPR54, *i.e.*, whether the substance is a potential agonist or an antagonist of GPR54, where the method comprises:

- (a) providing test cells by transfecting cells with an expression vector that directs the expression of GPR54 in the cells;
- (b) exposing the test cells to the substance;
- (c) measuring the amount of binding of the substance to GPR54 in the test cells;

(d) comparing the amount of binding of the substance to GPR54 in the test cells with the amount of binding of the substance to control cells that have not been transfected with GPR54;

5 wherein if the amount of binding of the substance is greater in the test cells as compared to the control cells, the substance is capable of binding to GPR54. Determining whether the substance is an agonist or antagonist can then be accomplished by the use of functional assays such as, *e.g.*, the assay involving the use of promiscuous G-proteins described below.

10 The conditions under which step (b) of the method is practiced are conditions that are typically used in the art for the study of protein-ligand interactions: *e.g.*, physiological pH; salt conditions such as those represented by such commonly used buffers as PBS or in tissue culture media; a temperature of about 4°C to about 55°C.

15 In a particular embodiment of the above-described methods, the cells are eukaryotic cells. In another embodiment, the cells are mammalian cells. In other embodiments, the cells are L cells L-M(TK⁻) (ATCC CCL 1.3), L cells L-M (ATCC CCL 1.2), HEK 293 (ATCC CRL 1573), Raji (ATCC CCL 86), CV-1 (ATCC CCL 70), COS-1 (ATCC CRL 1650), COS-7 (ATCC CRL 1651), CHO-K1 (ATCC CCL 61), 3T3 (ATCC CCL 92), NIH/3T3 (ATCC CRL 1658), HeLa (ATCC CCL 2),
20 C127I (ATCC CRL 1616), BS-C-1 (ATCC CCL 26) or MRC-5 (ATCC CCL 171).

The assays described above can be carried out with cells that have been transiently or stably transfected with GPR54. Transfection is meant to include any method known in the art for introducing GPR54 into the test cells. For example, transfection includes calcium phosphate or calcium chloride mediated transfection,
25 lipofection, infection with a retroviral construct containing GPR54, and electroporation.

Where binding of the substance or ligand to GPR54 is measured, such binding can be measured by employing a labeled substance or ligand. The substance or ligand can be labeled in any convenient manner known to the art, *e.g.*,
30 radioactively, fluorescently, enzymatically.

In particular embodiments of the above-described methods, GPR54 has an amino acid sequence of SEQ.ID.NO.:3 or SEQ.ID.NO.:4.

The above-described methods can be modified in that, rather than exposing the test cells to the substance, membranes can be prepared from the test cells
35 and those membranes can be exposed to the substance. Such a modification utilizing

membranes rather than cells is well known in the art and is described in, *e.g.*, Hess *et al.*, 1992, Biochem. Biophys. Res. Comm. 184:260-268.

Accordingly, the present invention provides a method for determining whether a substance is capable of binding to GPR54 comprising:

- 5 (a) providing test cells by transfecting cells with an expression vector that directs the expression of GPR54 in the cells;
- (b) preparing membranes containing GPR54 from the test cells and exposing the membranes to a ligand of GPR54 under conditions such that the ligand binds to the GPR54 in the membranes;
- 10 (c) subsequently or concurrently to step (b), exposing the membranes from the test cells to a substance;
- (d) measuring the amount of binding of the ligand to the GPR54 in the membranes in the presence and the absence of the substance;
- (e) comparing the amount of binding of the ligand to GPR54 in the
15 membranes in the presence and the absence of the substance where a decrease in the amount of binding of the ligand to GPR54 in the membranes in the presence of the substance indicates that the substance is capable of binding to GPR54.

In particular embodiments, GPR54 has an amino acid sequence of SEQ.ID.NO.:3 or SEQ.ID.NO.:4.

- 20 The present invention provides a method for determining whether a substance is capable of binding to GPR54 comprising:
 - (a) providing test cells by transfecting cells with an expression vector that directs the expression of GPR54 in the cells;
 - (b) preparing membranes containing GPR54 from the test cells and
25 exposing the membranes from the test cells to the substance;
 - (c) measuring the amount of binding of the substance to the GPR54 in the membranes from the test cells;
 - (d) comparing the amount of binding of the substance to GPR54 in the membranes from the test cells with the amount of binding of the substance to
30 membranes from control cells that have not been transfected with GPR54;
- where if the amount of binding of the substance to GPR54 in the membranes from the test cells is greater than the amount of binding of the substance to the membranes from the control cells, then the substance is capable of binding to GPR54.

In particular embodiments, GPR54 has an amino acid sequence of SEQ.ID.NO.:3 or SEQ.ID.NO.:4.

As a further modification of the above-described methods, RNA encoding GPR54 can be prepared, *e.g.*, by *in vitro* transcription using a plasmid containing GPR54 under the control of a bacteriophage T7 promoter, and the RNA can be microinjected into *Xenopus* oocytes in order to cause the expression of GPR54 in the oocytes. Substances are then tested for binding to the GPR54 expressed in the oocytes. Alternatively, rather than detecting binding, the effect of the substances on the electrophysiological properties of the oocytes can be determined.

The present invention includes assays by which GPR54 agonists and antagonists may be identified by their ability to stimulate or antagonize a functional response mediated by GPR54. One skilled in the art would be familiar with a variety of methods of measuring the functional responses of G-protein coupled receptors (see, *e.g.*, Lerner, 1994, Trends Neurosci. 17:142-146 [changes in pigment distribution in melanophore cells]; Yokomizo et al., 1997, Nature 387:620-624 [changes in cAMP or calcium concentration; chemotaxis]; Howard et al., 1996, Science 273:974-977 [changes in membrane currents in *Xenopus* oocytes]; McKee et al., 1997, Mol. Endocrinol. 11:415-423 [changes in calcium concentration measured using the aequorin assay]; Offermanns & Simon, 1995, J. Biol. Chem. 270:15175, 15180 [changes in inositol phosphate levels]).

Accordingly, the present invention provides a method of identifying agonists and antagonists of GPR54 comprising:

- (a) providing test cells by transfecting cells with an expression vector that directs the expression of GPR54 in the cells;
 - (b) exposing the test cells to a substance that is suspected of being an agonist or an antagonist of GPR54;
 - (c) measuring the amount of a functional response of the test cells that have been exposed to the substance;
 - (d) comparing the amount of the functional response exhibited by the test cells with the amount of the functional response exhibited by control cells;
- wherein if the amount of the functional response exhibited by the test cells differs from the amount of the functional response exhibited by the control cells, the substance is an agonist or antagonist of GPR54;

where the control cells are cells that have not been transfected with GPR54 but have been exposed to the substance or are test cells that have not been exposed to the substance.

In particular embodiments, GPR54 has an amino acid sequence of
5 SEQ.ID.NO.:3 or SEQ.ID.NO.:4.

In particular embodiments, the functional response is selected from the group consisting of: changes in pigment distribution in melanophore cells; changes in cAMP or calcium concentration; changes in membrane currents in *Xenopus* oocytes; and changes in inositol phosphate levels.

10 GPR54 belongs to the class of proteins known as G-protein coupled receptors (GPCRs). GPCRs transmit signals across cell membranes upon the binding of ligand. The ligand-bound GPCR interacts with a heterotrimeric G-protein, causing the $G\alpha$ subunit of the G-protein to disassociate from the $G\beta$ and $G\gamma$ subunits. The $G\alpha$ subunit can then go on to activate a variety of second messenger systems.

15 Generally, a particular GPCR is only coupled to a particular type of G-protein. Thus, to observe a functional response from the GPCR, it is necessary to ensure that the proper G-protein is present in the system containing the GPCR. It has been found, however, that there are certain G-proteins that are "promiscuous." These promiscuous G-proteins will couple to, and thus transduce a functional signal from,
20 virtually any GPCR. See Offermanns & Simon, 1995, J. Biol. Chem. 270:15175, 15180 (Offermanns). Offermanns described a system in which cells are transfected with expression vectors that result in the expression of one of a large number of GPCRs as well as the expression of one of the promiscuous G-proteins $G\alpha 15$ or $G\alpha 16$. Upon the addition of an agonist of the GPCR to the transfected cells, the
25 GPCR was activated and was able, via $G\alpha 15$ or $G\alpha 16$, to activate the β isoform of phospholipase C, leading to an increase in inositol phosphate levels in the cells.

Therefore, by making use of these promiscuous G-proteins as in Offermanns, it is possible to set up functional assays for GPR54, even in the absence of knowledge of the G-protein with which GPR54 is coupled *in vivo*. One possibility
30 is to create a fusion or chimeric protein composed of the extracellular and membrane spanning portion of GPR54 fused to a promiscuous G-protein. Such a fusion protein would be expected to transduce a signal following binding of ligand to the GPR54 portion of the fusion protein. Accordingly, the present invention provides a method of identifying antagonists of GPR54 comprising:

(a) providing cells that expresses a chimeric GPR54 protein fused at its C-terminus to a promiscuous G-protein;

(b) exposing the cells to an agonist of GPR54;

(c) subsequently or concurrently to step (b), exposing the cells to a substance that is a suspected antagonist of GPR54;

(d) measuring the level of inositol phosphates in the cells; where a decrease in the level of inositol phosphates in the cells in the presence of the substance as compared to the level of inositol phosphates in the cells in the absence of the substance indicates that the substance is an antagonist of GPR54.

Another possibility for utilizing promiscuous G-proteins in connection with GPR54 includes a method of identifying agonists of GPR54 comprising:

(a) providing cells that expresses both GPR54 and a promiscuous G-protein;

(b) exposing the cells to a substance that is a suspected agonist of GPR54;

(c) measuring the level of inositol phosphates in the cells; where an increase in the level of inositol phosphates in the cells as compared to the level of inositol phosphates in the cells in the absence of the suspected agonist indicates that the substance is an agonist of GPR54.

Levels of inositol phosphates can be measured by monitoring calcium mobilization. Intracellular calcium mobilization is typically assayed in whole cells under a microscope using fluorescent dyes or in cell suspensions via luminescence using the aequorin assay.

In a particular embodiment of the above-described method, the cells are eukaryotic cells. In another embodiment, the cells are mammalian cells. In other embodiments, the cells are L cells L-M(TK⁻) (ATCC CCL 1.3), L cells L-M (ATCC CCL 1.2), 293 (ATCC CRL 1573), Raji (ATCC CCL 86), CV-1 (ATCC CCL 70), COS-1 (ATCC CRL 1650), COS-7 (ATCC CRL 1651), CHO-K1 (ATCC CCL 61), 3T3 (ATCC CCL 92), NIH/3T3 (ATCC CRL 1658), HeLa (ATCC CCL 2), C127I (ATCC CRL 1616), BS-C-1 (ATCC CCL 26), MRC-5 (ATCC CCL 171), *Xenopus* oocytes, or *Xenopus* melanophores.

In a particular embodiment of the above-described method, the cells are transfected with expression vectors that direct the expression of GPR54 and the promiscuous G-protein in the cells.

The conditions under which step (b) of the method is practiced are conditions that are typically used in the art for the study of protein-ligand interactions: *e.g.*, physiological pH; salt conditions such as those represented by such commonly used buffers as PBS or in tissue culture media; a temperature of about 4°C to about 55°C.

In a particular embodiment of the above-described method, the promiscuous G-protein is selected from the group consisting of Gα15 or Gα16. Expression vectors containing Gα15 or Gα16 are known in the art. See, *e.g.*, Offermanns; Buhl *et al.*, 1993, FEBS Lett. 323:132-134; Amatruda *et al.*, 1993, J. Biol. Chem. 268:10139-10144.

The above-described assay can be modified to form a method to identify antagonists of GPR54. Such a method is also part of the present invention and comprises:

- (a) providing cells that expresses both GPR54 and a promiscuous G-protein;
 - (b) exposing the cells to a substance that is an agonist of GPR54;
 - (c) subsequently or concurrently to step (b), exposing the cells to a substance that is a suspected antagonist of GPR54;
 - (d) measuring the level of inositol phosphates in the cells;
- where a decrease in the level of inositol phosphates in the cells in the presence of the suspected antagonist as compared to the level of inositol phosphates in the cells in the absence of the suspected antagonist indicates that the substance is an antagonist of GPR54.

In a particular embodiment of the above-described method, the cells are eukaryotic cells. In another embodiment, the cells are mammalian cells. In other embodiments, the cells are L cells L-M(TK⁻) (ATCC CCL 1.3), L cells L-M (ATCC CCL 1.2), 293 (ATCC CRL 1573), Raji (ATCC CCL 86), CV-1 (ATCC CCL 70), COS-1 (ATCC CRL 1650), COS-7 (ATCC CRL 1651), CHO-K1 (ATCC CCL 61), 3T3 (ATCC CCL 92), NIH/3T3 (ATCC CRL 1658), HeLa (ATCC CCL 2), C127I (ATCC CRL 1616), BS-C-1 (ATCC CCL 26), MRC-5 (ATCC CCL 171), *Xenopus* oocytes, or *Xenopus* melanophores.

The conditions under which steps (b) and (c) of the method are practiced are conditions that are typically used in the art for the study of protein-ligand interactions: *e.g.*, physiological pH; salt conditions such as those represented by such

commonly used buffers as PBS or in tissue culture media; a temperature of about 4°C to about 55°C.

5 In a particular embodiment of the above-described method, the cells are transfected with expression vectors that direct the expression of GPR54 and the promiscuous G-protein in the cells.

In a particular embodiment of the above-described method, the promiscuous G-protein is selected from the group consisting of Gα15 or Gα16.

In particular embodiments of the above-described methods, GPR54 has an amino acid sequence of SEQ.ID.NO.:3 or SEQ.ID.NO.:4.

10 While the above-described methods are explicitly directed to testing whether “a” substance is an agonist or antagonist of GPR54, it will be clear to one skilled in the art that such methods can be adapted to test collections of substances, *e.g.*, combinatorial libraries, to determine whether any members of such collections are activators or inhibitors of GPR54. Accordingly, the use of collections of
15 substances, or individual members of such collections, as the substance in the above-described methods is within the scope of the present invention.

Agonists and antagonists of GPR54 that are identified by the above-described methods are expected to have utility in the treatment of diseases that involve the inappropriate expression of GPR54. In particular, given the resemblance
20 between GPR54 and the galanin receptors, it is expected that agonists and antagonists of GPR54 will have pharmacological activity and be useful in a manner similar to that in which agonists and antagonists of the galanin receptors are useful. Therefore, agonists and antagonists of GPR54 are expected to be useful in the treatment of: eating disorders and obesity; Alzheimer’s disease and other disorders affecting
25 memory; pain; sexual disorders; and growth hormone imbalances.

The present invention includes pharmaceutical compositions comprising agonists and antagonists of GPR54. The agonists and antagonists are generally combined with pharmaceutically acceptable carriers to form pharmaceutical compositions. Examples of such carriers and methods of formulation of
30 pharmaceutical compositions containing agonists and antagonists and carriers can be found in Remington’s Pharmaceutical Sciences. To form a pharmaceutically acceptable composition suitable for effective administration, such compositions will contain a therapeutically effective amount of the agonists and antagonists.

Therapeutic or prophylactic compositions are administered to an individual in amounts sufficient to treat or prevent conditions where GPR54 activity is abnormal. The effective amount can vary according to a variety of factors such as the individual's condition, weight, gender, and age. Other factors include the mode of administration. The appropriate amount can be determined by a skilled physician.

Compositions can be used alone at appropriate dosages. Alternatively, co-administration or sequential administration of other agents can be desirable.

The compositions can be administered in a wide variety of therapeutic dosage forms in conventional vehicles for administration. For example, the compositions can be administered in such oral dosage forms as tablets, capsules (each including timed release and sustained release formulations), pills, powders, granules, elixirs, tinctures, solutions, suspensions, syrups and emulsions, or by injection. Likewise, they can also be administered in intravenous (both bolus and infusion), intraperitoneal, subcutaneous, topical with or without occlusion, or intramuscular form, all using forms well known to those of ordinary skill in the pharmaceutical arts.

Advantageously, compositions can be administered in a single daily dose, or the total daily dosage can be administered in divided doses of two, three or four times daily. Furthermore, compositions can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in that art. To be administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.

The dosage regimen utilizing the compositions is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal, hepatic and cardiovascular function of the patient; and the particular composition thereof employed. A physician of ordinary skill can readily determine and prescribe the effective amount of the composition required to prevent, counter or arrest the progress of the condition. Optimal precision in achieving concentrations of composition within the range that yields efficacy without toxicity requires a regimen based on the kinetics of the composition's availability to target sites. This involves a consideration of the distribution, equilibrium, and elimination of a composition.

The present invention also includes methods of expressing GPR54 in recombinant systems and then utilizing the recombinantly expressed GPR54 receptor protein for counter-screening. When screening compounds in order to identify potential pharmaceuticals that specifically interact with a target receptor, it is
5 necessary to ensure that the compounds identified are as specific as possible for the target receptor. To do this, it is necessary to screen the compounds against as wide an array as possible of receptors that are similar to the target receptor. Thus, in order to find compounds that are potential pharmaceuticals that interact with receptor A, it is necessary not only to ensure that the compounds interact with receptor A (the “plus
10 target”) and produce the desired pharmacological effect through receptor A, it is also necessary to determine that the compounds do not interact with receptors B, C, D, *etc.* (the “minus targets”). In general, as part of a screening program, it is important to have as many minus targets as possible (see Hodgson, 1992, *Bio/Technology* 10:973-980, at 980). Therefore, GPR54 proteins and DNA encoding GPR54 proteins have
15 utility in counter-screens. That is, they can be used as “minus targets” in counter-screens in connection with screening projects designed to identify compounds that specifically interact with other G-protein coupled receptors.

The DNA of the present invention, or hybridization probes based upon the DNA, can be used in chromosomal mapping studies in order to identify the precise
20 chromosomal location of the GPR54 gene or of genes encoding proteins related to GPR54. While the present inventors have determined that the human GPR54 gene is located at chromosome 19p13.3, it may be desirable to perform mapping studies to even more precisely locate the human GPR54 gene. Such mapping studies can be carried out using well-known genetic and/or chromosomal mapping techniques such
25 as, *e.g.*, linkage analysis with respect to known chromosomal markers or *in situ* hybridization. See, *e.g.*, Verma et al., 1988, Human Chromosomes: A Manual of Basic Techniques, Pergamon Press, New York, NY. After identifying the precise chromosomal location of the GPR54 gene or genes encoding proteins related to GPR54, this information can be compared with the locations of known disease-
30 causing genes contained in genetic map data (such as the data found in the genome issue of *Science* (1994, 265:1981-2144). In this way, one can correlate the chromosomal location of the GPR54 gene or of genes encoding proteins related to GPR54 with the locations of known disease-causing genes and thus help to limit the region of DNA containing such disease-causing genes. This will simplify the process
35 of cloning such disease-causing genes. Also, once linkage between the precise

chromosomal location of the GPR54 gene or of genes encoding proteins related to GPR54 and the locations of a known disease-causing gene is established, that linkage can be used diagnostically to identify restriction fragment length polymorphisms (RFLPs) in the vicinity of the GPR54 gene or of genes encoding proteins related to GPR54. Such RFLPs will be associated with the disease-causing gene and thus can be used to identify individuals carrying the disease-causing gene.

For such chromosomal mapping studies as described herein, it may be advantageous to use, in addition to the DNA of the present invention, the reverse complement of the DNA of the present invention or RNA corresponding to the DNA of the present invention.

Nucleotide sequences that are complementary to the GPR54 sequences disclosed herein can be synthesized for use in antisense therapy. Such antisense molecules can be DNA, stable derivatives of DNA such as phosphorothioates or methyl phosphonates, RNA, stable derivatives of RNA such as 2'-O-alkyl RNA, or other forms of GPR54 antisense molecules. GPR54 antisense molecules can be introduced into cells by a variety of methods, *e.g.*, microinjection, liposome encapsulation, or by expression from vectors harboring the antisense sequence. GPR54 antisense therapy is expected to be particularly useful in the treatment of conditions where it is beneficial to reduce GPR54 activity.

The present invention also includes antibodies to the GPR54 protein. Such antibodies may be polyclonal antibodies or monoclonal antibodies and are useful in treating disorders that involve the inappropriate expression or activity of the GPR54 protein. The antibodies of the present invention are raised against the entire GPR54 protein or against suitable antigenic fragments of the protein that are coupled to suitable carriers, *e.g.*, serum albumin or keyhole limpet hemocyanin, by methods well known in the art. Methods of identifying suitable antigenic fragments of a protein are known in the art. See, *e.g.*, Hopp & Woods, 1981, *Proc. Natl. Acad. Sci. USA* 78:3824-3828; and Jameson & Wolf, 1988, *CABIOS (Computer Applications in the Biosciences)* 4:181-186.

For the production of polyclonal antibodies, GPR54 protein or an antigenic fragment, coupled to a suitable carrier, is injected on a periodic basis into an appropriate non-human host animal such as, *e.g.*, rabbits, sheep, goats, rats, mice. The animals are bled periodically and sera obtained are tested for the presence of antibodies to the injected antigen. The injections can be intramuscular, intraperitoneal, subcutaneous, and the like, and can be accompanied with adjuvant.

For the production of monoclonal antibodies, GPR54 protein or an antigenic fragment, coupled to a suitable carrier, is injected into an appropriate non-human host animal as above for the production of polyclonal antibodies. In the case of monoclonal antibodies, the animal is generally a mouse. The animal's spleen cells are then immortalized, often by fusion with a myeloma cell, as described in Kohler & Milstein, 1975, Nature 256:495-497. For a fuller description of the production of monoclonal antibodies, see Antibodies: A Laboratory Manual, Harlow & Lane, eds., Cold Spring Harbor Laboratory Press, 1988.

Gene therapy may be used to introduce GPR54 polypeptides into the cells of target organs. Nucleotides encoding GPR54 polypeptides can be ligated into viral vectors which mediate transfer of the nucleotides by infection of recipient cells. Suitable viral vectors include retrovirus, adenovirus, adeno-associated virus, herpes virus, vaccinia virus, and polio virus based vectors. Alternatively, nucleotides encoding GPR54 polypeptides can be transferred into cells for gene therapy by non-viral techniques including receptor-mediated targeted transfer using ligand-nucleotide conjugates, lipofection, membrane fusion, or direct microinjection. These procedures and variations thereof are suitable for *ex vivo* as well as *in vivo* gene therapy. Gene therapy with GPR54 polypeptides will be particularly useful for the treatment of diseases where it is beneficial to elevate GPR54 activity.

A cDNA fragment encoding full-length GPR54 can be isolated from an appropriate human cDNA library by using the polymerase chain reaction (PCR) employing suitable primer pairs. Such primer pairs can be selected based upon the cDNA sequence for GPR54 shown in Figure 1 as SEQ.ID.NO.:1. Suitable primer pairs would be, *e.g.*:

5'-ATG CAC ACC GTG GCT ACG TCC-3' (SEQ.ID.NO.:11) and
5'-TCA GAG AGG GGC GTT GTC CTC-3' (SEQ.ID.NO.:12).

The above primers may contain restriction sites in their 5' ends to facilitate cloning of the amplified cDNA into suitable vectors, *e.g.*, pcDNA3.1. The above primers are meant to be illustrative. One skilled in the art would recognize that a variety of other suitable primers can be designed.

PCR reactions can be carried out with a variety of thermostable enzymes including but not limited to AmpliTaq, AmpliTaq Gold, or Vent polymerase. For AmpliTaq, reactions can be carried out in 10 mM Tris-Cl, pH 8.3, 2.0 mM

MgCl₂, 200 µM for each dNTP, 50 mM KCl, 0.2 µM for each primer, 10 ng of DNA template, 0.05 units/µl of AmpliTaq. The reactions are heated at 95°C for 3 minutes and then cycled 35 times using the cycling parameters of 95°C, 20 seconds, 62°C, 20 seconds, 72°C, 3 minutes. In addition to these conditions, a variety of suitable PCR protocols can be found in PCR Primer, A Laboratory Manual, edited by C.W. Dieffenbach and G.S. Dveksler, 1995, Cold Spring Harbor Laboratory Press; or PCR Protocols: A Guide to Methods and Applications, Michael *et al.*, eds., 1990, Academic Press.

A suitable cDNA library from which a clone encoding GPR54 can be isolated would be a human cDNA library made from RNA from brain tissue. Such libraries can be prepared by methods well-known in the art. Alternatively, several commercially available libraries would be suitable, *e.g.*, cDNA libraries such as human fetal brain, catalog #937227 from Stratagene, Inc., La Jolla, CA, USA, and human brain hypothalamus, catalog #HL1172a, from Clontech Laboratories, Inc., Palo Alto, CA, USA. The primary clones of such libraries can be subdivided into pools with each pool containing approximately 20,000 clones and each pool can be amplified separately.

By this method, a cDNA fragment encoding an open reading frame of 398 amino acids (SEQ.ID.NO.:3) can be obtained. This cDNA fragment can be cloned into a suitable cloning vector or expression vector. For example, the fragment can be cloned into the mammalian expression vector pcDNA3.1 (Invitrogen, San Diego, Ca). GPR54 protein can then be produced by transferring an expression vector encoding GPR54 into suitable host cells and growing the host cells under appropriate conditions. GPR54 protein can then be isolated by methods well known in the art.

As an alternative to the above-described PCR method, a cDNA clone encoding GPR54 can be isolated from a cDNA library using as a probe oligonucleotides specific for GPR54 and methods well known in the art for screening cDNA libraries with oligonucleotide probes. Such methods are described in, *e.g.*, Sambrook *et al.*, 1989, *Molecular Cloning: A Laboratory Manual*; Cold Spring Harbor Laboratory, Cold Spring Harbor, New York; Glover, D.M. (ed.), 1985, *DNA Cloning: A Practical Approach*, MRL Press, Ltd., Oxford, U.K., Vol. I, II. Oligonucleotides that are specific for GPR54 and that can be used to screen cDNA libraries can be readily designed based upon the cDNA sequence of GPR54 shown in Figure 1 as SEQ.ID.NO.:1 and can be synthesized by methods well-known in the art.

Genomic clones containing the GPR54 gene can be obtained from commercially available human PAC or BAC libraries, *e.g.*, from Research Genetics, Huntsville, AL. Alternatively, one may prepare genomic libraries, for example in P1 artificial chromosome vectors, from which genomic clones containing the GPR54 can be isolated, using probes based upon the GPR54 nucleotide sequences disclosed herein. Methods of preparing such libraries are known in the art (Ioannou *et al.*, 1994, Nature Genet. 6:84-89).

The following non-limiting examples are presented to better illustrate the invention.

EXAMPLE 1

PCR amplification and cDNA library screening

A rat brain 5' Stretch cDNA library (Clontech) was amplified by the polymerase chain reaction (PCR) using proof-reading *Pfu* polymerase (Stratagene) and degenerate oligonucleotides based upon sequences encoding GPCR conserved transmembrane (TM) region 3

P1: 5'-CTGACCGGCATGABDETFGADCGHTA-3' (SEQ.ID.NO.:9)
and transmembrane (TM) region 7

P2: 5'-GAAGGCGTAGAFBAIJGGKTT)-3' (SEQ.ID.NO.:10)

where B = C or G, D = C or T, E = A or G or T, F = C or G or T, H = A or C, I = A or C or G or T, J = A or C or G, K = A or G.

PCR conditions were as follows: denaturation at 94°C for 30 sec, annealing at 55, 48, 45, 42, or 40°C for 40 sec, and extension at 72°C for 30 sec, for 30 cycles, followed by a 7 min extension at 72°C. The PCR products were extracted with phenol/chloroform, precipitated with ethanol and electrophoresed on a low melting point agarose gel. PCR product bands in the expected size range were excised from the gel, ligated into the *EcoRV* site of pBluescript SK(-) (Stratagene)

and sequenced. One insert appeared to encode a novel GPCR and was labeled with [^{32}P] dCTP- α (NEN) by nick translation (Amersham) and used to screen the same library amplified above as previously described (Marchese et al., 1994, Genomics 23:609-618). Positive phage clones were plaque purified and their inserts amplified
5 by PCR using *Pfu* polymerase and primers flanking the *lgt11* *EcoRI* cloning site. The PCR products were blunt-end ligated into the *EcoRV* site of pBluescript SK(-) (Stratagene) and sequenced on both strands.

EXAMPLE 2

10 Northern blot analysis

Rat mRNAs from several rat tissues were extracted as described previously (Marchese et al., 1994, Genomics 23:609-618). Briefly, total RNA was extracted by the method of Chomczynski & Sacchi, 1987, Anal. Biochem. 162:156-159 and poly (A) $^{+}$ RNA isolated using oligo(dT) cellulose spin columns (Pharmacia,
15 Uppsala, Sweden). RNA was denatured and size fractionated on a 1% formaldehyde agarose gel, transferred onto nylon membrane and immobilized by UV irradiation. The blots were hybridized with a ^{32}P -labeled DNA fragment encoding GPR54, washed with 2X SSPE and 0.1% SDS at 50°C for 20 min and again with 0.1X SSPE and 0.1% SDS at 50°C for 2 h and exposed to X-ray film at -70°C in the presence of
20 an intensifying screen.

EXAMPLE 3

In situ hybridization analysis

An ^{35}S -labeled DNA fragment encoding GPR54 was used as a probe
25 for *in situ* hybridization. Preparation of rat brain sections and *in situ* hybridization procedures were done as previously described (O'Dowd et al., 1996, FEBS Lett 394:325-329).

EXAMPLE 4

Expression of GPR54 cDNA in COS-7 mammalian cells

The African Green Monkey SV40 transformed kidney cell line (COS-7 cells), obtained from the American Type Culture Collection, was grown in
5 Dulbecco's modified Eagle's medium supplemented with 10% heat-inactivated fetal calf serum (Sigma), 50 units/ml penicillin, 50 µg/ml streptomycin (Flow Laboratories, McLean, VA), and 2 mM glutamine (Flow Laboratories) at 37°C under an atmosphere of 6% CO₂. 5 X 10⁶ cells per 175- cm² culture flask were seeded in 20 ml of media and transiently transfected at 80% confluence with either 2.75, 5.5, or 11.65 µg of
10 pcDNA3-GPR54 or pcNeo-hGALR1 plasmids and 70 µl of LipofectAMINE reagent (Life Technologies, Inc.), following recommendations of the manufacturer. Two days after transfection, cells were harvested following dissociation in enzyme-free dissociation solution (Specialty Media, Lavallete, NJ).

15

EXAMPLE 5

Membrane preparation and radioligand binding assays

Membranes were prepared from transfected cells by disruption by pressurized nitrogen cavitation in ice-cold membrane buffer (10 mM Tris, pH 7.4, 10 mM phenylmethylsulfonylfluoride, 10 mM phosphoramidon). After a low speed
20 (1100 x g for 10 min. at 4°C) and a high speed centrifugation (38,700 x g for 15 min. at 4°C), membranes were resuspended in buffer and their protein concentration determined (Bio-Rad assay kit). Binding of ¹²⁵I-human galanin (specific activity of 2200 Ci/mmol, DuPont NEN) was measured in membranes using a buffer of 25 mM Tris, pH 7.4, 0.3% BSA, 2 mM MgCl₂, 4 mg/ml phosphoramidon, and 10 mM
25 leupeptin in a total volume of 250 µl. 200 pM of ¹²⁵I-human galanin was used. Reactions were initiated by the addition of membranes and the incubation was allowed to proceed at room temperature for 2 hours. Non-specific binding was defined as the amount of radioactivity remaining bound in the presence of 10 mM unlabeled human galanin. Incubations were terminated by rapid filtration through
30 GF/C filters which had been presoaked with 0.1% polyethylamine using a TOMTEC (Orange, CT) cell harvester.

The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are intended to fall within the scope of the appended claims.

Various publications are cited herein, the disclosures of which are incorporated by reference in their entireties.

WHAT IS CLAIMED:

1. An isolated DNA comprising nucleotides encoding a polypeptide having the amino acid sequence SEQ.ID.NO.:3 or SEQ.ID.NO.:4.
2. The DNA molecule of claim 1 comprising a nucleotide sequence selected from the group consisting of SEQ.ID.NO.:1; positions 1-1,194 of SEQ.ID.NO.:1; SEQ.ID.NO.:2; and positions 61-1,245 of SEQ.ID.NO.:2.
3. A DNA molecule that hybridizes under stringent conditions to the DNA of claim 1.
4. An expression vector comprising the DNA of claim 1.
5. A recombinant host cell comprising the DNA of claim 1.
6. An isolated polypeptide comprising a GPR54 protein having the amino acid sequence SEQ.ID.NO.:3 or SEQ.ID.NO.:4.
7. The isolated polypeptide of claim 6 that is substantially free from other proteins.
8. The isolated polypeptide of claim 6 containing a single amino acid substitution.
9. The isolated polypeptide of claim 6 containing two or more amino acid substitutions where the substitutions are conservative and do not occur in positions where GPR54 and any of the rat GALR1, GALR2, or GALR3 receptors share the same amino acid.
10. A method for determining whether a substance is an agonist or antagonist of GPR54 comprising:
 - (a) transfecting cells with an expression vector encoding GPR54;

- (b) allowing the transfected cells to grow for a time sufficient to allow GPR54 to be expressed;
- (c) exposing the cells to a labeled ligand of GPR54 in the presence and in the absence of the substance;
- 5 (d) measuring the binding of the labeled ligand to GPR54; where if the amount of binding of the labeled ligand is less in the presence of the substance than in the absence of the substance, then the substance is an agonist or antagonist of GPR54;
- where GPR54 has the amino acid sequence SEQ.ID.NO.:3 or
- 10 SEQ.ID.NO.:4.

11. A method for determining whether a substance is capable of binding to GPR54 comprising:
- (a) providing test cells by transfecting cells with an expression
- 15 vector that directs the expression of GPR54 in the cells;
- (b) exposing the test cells to the substance;
- (c) measuring the amount of binding of the substance to GPR54 in the test cells;
- (d) comparing the amount of binding of the substance to GPR54 in
- 20 the test cells with the amount of binding of the substance to control cells that have not been transfected with GPR54;
- wherein if the amount of binding of the substance is greater in the test cells as compared to the control cells, the substance is capable of binding to GPR54;
- where GPR54 has the amino acid sequence SEQ.ID.NO.:3 or
- 25 SEQ.ID.NO.:4.

12. A method of identifying agonists and antagonists of GPR54 comprising:
- (a) providing test cells by transfecting cells with an expression
- 30 vector that directs the expression of GPR54 in the cells;
- (b) exposing the test cells to a substance that is suspected of being an agonist or an antagonist of GPR54;
- (c) measuring the amount of a functional response of the test cells that have been exposed to the substance;

- (d) comparing the amount of the functional response exhibited by the test cells with the amount of the functional response exhibited by control cells;
wherein if the amount of the functional response exhibited by the test cells differs from the amount of the functional response exhibited by the control cells,
5 the substance is an agonist or antagonist of GPR54;
where the control cells are cells that have not been transfected with GPR54 but have been exposed to the substance or are test cells that have not been exposed to the substance;
where GPR54 has the amino acid sequence SEQ.ID.NO.:3 or
10 SEQ.ID.NO.:4.
13. An antibody that binds specifically to GPR54 where GPR54 has the amino acid sequence SEQ.ID.NO.:3 or SEQ.ID.NO.:4.

FIGURE 1A

Met	His	Thr	Val	Ala	Thr	Ser	Gly	Pro	Asn	Ala	Ser	Trp	Gly	Ala	Pro	Ala	Asn	Ala
ATG	CAC	ACC	GTG	GCT	ACG	TCC	GGA	CCC	AAC	GCG	TCC	TGG	GGG	GCA	CCG	GCC	AAC	GCC
		9			18			27			36			45			54	
Ser	Gly	Cys	Pro	Gly	Cys	Gly	Ala	Asn	Ala	Ser	Asp	Gly	Pro	Val	Pro	Ser	Pro	Arg
TCC	GCG	TGC	CCG	GCG	TGT	GCG	GCC	AAC	GCC	TGG	GAC	GCG	CCA	GTC	CCT	TGG	CCG	CGG
		66			75			84			93			102			111	120
Asp	Ala	Trp	Leu	Val	Pro	Leu	Phe	Phe	Ala	Ala	Leu	Met	Leu	Leu	Gly	Leu	Val	Gly
GAC	GCC	TGG	CTC	GTG	CCG	CTC	TTC	TTC	GCG	GCG	CTG	ATG	CTG	CTG	GCG	CTG	GTG	GGG
		129			138			147			156			165			174	183
Leu	Val	Ile	Tyr	Val	Ile	Cys	Arg	His	Lys	Pro	Met	Arg	Thr	Val	Thr	Asn	Phe	Tyr
CTG	GTC	ATC	TAC	GTC	ATC	TGC	CCG	CAC	AAG	CCG	ATG	CCG	ACC	GTG	ACC	AAC	TTC	TAC
		192			201			210			219			228			237	246
Asn	Leu	Ala	Ala	Thr	Asp	Val	Thr	Phe	Leu	Leu	Cys	Cys	Val	Pro	Phe	Thr	Ala	Leu
AAC	CTG	GCG	GCC	ACG	GAC	GTG	ACC	TTC	CTC	CTG	TGC	TGC	GTC	CCC	TTC	ACG	GCC	CTG
		255			264			273			282			291			300	309
Pro	Leu	Pro	Gly	Trp	Val	Leu	Gly	Asp	Phe	Met	Cys	Lys	Phe	Val	Asn	Tyr	Ile	Gln
CCG	CTG	CCC	GCG	TGG	GTG	CTG	GCG	GAC	TTC	ATG	TGC	AAG	TTC	GTC	AAC	TAC	ATC	CAG
		318			327			336			345			354			363	372
Ser	Val	Gln	Ala	Thr	Cys	Ala	Thr	Leu	Thr	Ala	Met	Ser	Val	Asp	Arg	Trp	Tyr	Val
TGG	GTG	CAG	GCC	ACG	TGT	GCC	ACT	CTG	ACC	GCC	ATG	AGT	GTG	GAC	CCG	TGG	TAC	GTG
		381			390			399			408			417			426	435
Phe	Pro	Leu	Arg	Ala	Leu	His	Arg	Arg	Thr	Pro	Arg	Leu	Ala	Leu	Ala	Val	Ser	Leu
TTC	CCG	TTG	CGC	GCC	CTG	CAC	CCG	CGC	ACG	CCC	CGC	CTG	GCG	CTG	GCT	GTC	AGC	CTC
		444			453			462			471			480			489	498
Trp	Val	Gly	Ser	Ala	Ala	Val	Ser	Ala	Pro	Val	Leu	Ala	Leu	His	Arg	Leu	Ser	Pro
TGG	GTA	GCG	TCT	GCG	GCG	GTG	TCT	GCG	CCG	GTG	CTC	GCC	CTG	CAC	CCG	CTG	TCA	CCC
		507			516			525			534			543			552	561
Arg	Ala	Tyr	Cys	Ser	Glu	Ala	Phe	Pro	Ser	Arg	Ala	Leu	Glu	Arg	Ala	Phe	Ala	Leu
CGC	GCC	TAC	TGC	AGT	GAG	GCC	TTC	CCC	AGC	CGC	GCC	CTG	GAG	CGC	GCC	TTC	GCA	CTG
		570			579			588			597			606			615	624
Leu	Leu	Ala	Leu	Tyr	Leu	Leu	Pro	Leu	Leu	Ala	Thr	Cys	Ala	Cys	Tyr	Ala	Ala	Met
CTG	CTG	GCG	CTG	TAC	CTG	CTG	CCG	CTG	CTC	GCC	ACC	TGC	GCC	TGC	TAT	GCG	GCC	ATG
		633			642			651			660			669			678	687

FIGURE 1B

His Leu Gly Arg Val Ala Val Arg Pro Ala Pro Ala Asp Ser Ala Leu Gln Gly Gln Val Leu
CAC CTG GGC CGG GTC GCC GTG CCG CCC GCG CCC GCC GAT AGC GCC CTG CAG GGG CAG GTG CTG
696 705 714 723 732 741 750

Ala Glu Arg Ala Gly Ala Val Arg Ala Lys Val Ser Arg Leu Val Ala Ala Val Val Leu Leu
GCA GAG CGC GCA GGC GCC GTG CCG GCC AAG GTC TCG CCG CTG GTG GCG GCC GTG GTC CTC CTC
759 768 777 786 795 804 813

Phe Ala Ala Cys Trp Gly Pro Ile Gln Leu Phe Leu Val Leu Gln Ala Leu Gly Pro Ala Gly
TTC GCC GCC TGC TGG GGC CCC ATC CAG CTG TTC CTG GTG CTG CAG GCG CTG GGC CCC GCG GGC
822 831 840 849 858 867 876

Ser Trp His Pro Arg Ser Tyr Ala Ala Tyr Ala Leu Lys Thr Trp Ala His Cys Met Ser Tyr
TCC TGG CAC CCA CGC AGC TAC GCC GCC TAC GCG CTT AAG ACC TGG GCT CAC TGC ATG TCC TAC
885 894 903 912 921 930 939

Ser Asn Ser Ala Leu Asn Pro Leu Leu Tyr Ala Phe Leu Gly Ser His Phe Arg Gln Ala Phe
AGC AAC TCC GCG CTG AAC CCG CTG CTC TAC GCC TTC CTG GCG TCG CAC TTC CGA CAG GCC TTC
948 957 966 975 984 993 1002

Arg Arg Val Cys Pro Cys Ala Pro Arg Arg Pro Arg Arg Pro Arg Arg Pro Gly Pro Ser Asp
CGC CGC GTC TGC CCC TGC GCG CCG CCG CCG CCG CCG CCG CCG CCG CCG CCG CCG CCG CCG CCG CCG
1011 1020 1029 1038 1047 1056 1065

Pro Ala Ala Pro His Ala Glu Leu Leu Arg Leu Gly Ser His Pro Ala Pro Ala Arg Ala Gln
CCC GCA GCC CCA CAC GCG GAG CTG CTC CCG CTG GCG TCC CAC CCG GCC CCC GCC AGG GCG CAG
1074 1083 1092 1101 1110 1119 1128

Lys Pro Gly Ser Ser Gly Leu Ala Ala Arg Gly Leu Cys Val Leu Gly Glu Asp Asn Ala Pro
AAG CCA GGG AGC AGT GGG CTG GCC GCG CCG GCG CTG TGC GTC CTG GGG GAG GAC AAC GCC CCG
1137 1146 1155 1164 1173 1182 1191

Leu TER
CTC TGA

FIGURE 2A

CCA	CAG	TCC	CAG	GAC	GCA	ATC	TGT	GAA	GGC	TGC	CTG	GAG	GAG	GAG	GAG	GGC	GAC	AGG	GCC	9	18	27	36	45	54			
ATG	GCC	GCA	GAG	GCG	ACG	TTG	GGT	CCG	AAC	GTG	AGC	TGG	TGG	GCT	CCG	TCC	AAC	GCT	TCG	GGA	TGC	69	78	87	96	105	114	123
CCG	GGC	TGC	GGT	GTC	AAT	GCC	TCG	GAT	GGC	CCA	GGC	TCC	GCG	CCA	AGG	CCC	CTG	GAT	GCC	TGG	CTG	135	144	153	162	171	180	189
GTG	CCC	CTG	TTT	TTC	GCT	GCC	CTA	ATG	TTG	CTG	GGG	CTA	GTC	GGG	AAC	TCA	CTG	GTC	ATC	TTC	GTT	201	210	219	228	237	246	255
ATC	TGC	CGC	CAC	AAG	CAC	ATG	CAG	ACC	GTC	ACC	AAT	TTC	TAC	ATC	GCT	AAC	CTG	GCG	GCC	ACA	GAT	267	276	285	294	303	312	321
GTC	ACT	TTC	CTT	CTG	TGC	TGC	GTA	CCC	TTC	ACC	GCG	CTC	CTC	TAT	CCG	CTG	CCC	ACC	TGG	GTG	CTG	333	342	351	360	369	378	387
GGA	GAC	TTC	ATG	TGC	AAA	TTC	GTC	AAC	TAC	ATC	CAG	CAG	GTC	TCG	GTG	CAA	GCC	ACA	TGT	GCC	ACT	399	408	417	426	435	444	453
TTG	ACA	GCC	ATG	AGT	GTG	GAC	CGC	TGG	TAC	GTG	ACT	GTG	TTC	CCG	CTG	CGT	GCA	CTT	CAC	CGC	CGC	465	474	483	492	501	510	519
ACT	CCG	CGC	CTG	GCC	CTG	ACT	GTC	AGC	CTT	AGC	ATC	TGG	GTG	GGT	TCC	GCA	GCT	GTT	TCC	GCC	CCG	531	540	549	558	567	576	585
CTG	CTG	GCT	CTG	CAC	CGC	CTG	TCG	CCC	GGG	CCT	CAC	ACC	TAC	TGC	AGT	GAG	GCG	TTT	CCC	AGC	CGT	597	606	615	624	633	642	651
GCC	CTG	GAG	CGC	GCT	TTC	GCG	CTC	TAC	AAC	CTG	CTG	GCC	CTA	TAC	CTG	CTG	CCG	CTG	CTC	GCC	ACC	663	672	681	690	699	708	717

FIGURE 2B

TGC GCC TGC TAC GGT GCC ATG CTG CGC CAC CTG GGC CGC GCC GCT GTA CGC CCC GCA CCC ACT GAT
 729 738 747 756 765 774 783

GGC GCC CTG CAG GGG CAG CTG CTA GCA CAG CGC GCT GGA GCA GTG CGC ACC AAG GTC TCC CGG CTG
 795 804 813 822 831 840 849

GTG GCC GCT GTC GTC CTG CTC TTC GCC GCC TGC TGG GGC CCG ATC CAG CTG TTC CTG GTG CTT CAA
 861 870 879 888 897 906 915

GCC CTG CCG CTC GGG GGC CTG GCA CCC TCG AAG CTA TGC GCC TAC GCG CTC AAG ATC TGG GCT CAC
 927 936 945 954 963 972 981

TGC ATG TCC TAC AGC AAT TCT GCG CTC AAC CCG CTG CTC TAT GCC TTC CTG GGT TCC CAC TTC AGA
 993 1002 1011 1020 1029 1038 1047

CAG GCC TTC TGC CGC GTG TGC CCC TGC GGC CCG CAA CGC CAG CGT CGG CCC CAC GCG TCA GCG CAC
 1059 1068 1077 1086 1095 1104 1113

TCG GAC CGA GCC GCA CCC CAT AGT GTG CCG CAC AGC CCG GCT GCG CAC CCT GTC CGG GTC AGG ACC
 1125 1134 1143 1152 1161 1170 1179

CCC GAG CCT GGG AAC CCT GTG GTG CAC TCG CCC TCT GTT CAG GAT GAA CAC ACT GCC CCA CTC TGA
 1191 1200 1209 1218 1227 1236 1245

GCT GCC

FIGURE 3

MHTVATSGPN ASWGAPANAS GCPGCGANAS DGPVPSPRAY DAWLVPLFFA ALMLLGVLGN 60

SLVIYVICRH KPMRTVTNFI IANLAATDVT FLLCCVPFTA LLYPLPGWVL GDFMCKFVNY 120

IQQVSVQATC ATLTAMSVDR WYVTVFPLRA LHRRTPLAL AVSLSIWVGS AAVSAPVLAL 180

HRLSPGPRAY CSEAFPSRAL ERAFALYNLL ALYLLPLLAT CACYAAMLRH LGRVAVRPAP 240

ADSALQGQVL AERAGAVRAK VSRLVAAVVL LFAACWGPIQ LFLVLQALGP AGSWHPRSYA 300

AYALKTWAHC MSYSNSALNP LLYAFLGSHF RQAFRRVCPC APRRPRRPRR PGPSDPAAFH 360

AELLRLGSHF APARAQKPGS SGLAARGLCV LGEDNAPL 398

FIGURE 4

MAAEATLGPN VSWWAPSNAS GCPGCGVNAS DGPGSAPRPL DAWLVPLFFA ALMLLGLVGN SLVIFVICRH
KHMOTVTNFI IANLAATDVT FLLCCVPFTA LLYPLPTWVL GDFMCKFVNY IQQVSVQATC ATLTAMSVDR
WYVTVFPLRA LHRRTFRLAL TVSLSIWVGS AAVSAPVLAL HRLSPGPHTY CSEAFPSRAL ERAFALYNLL
ALYLLPLLAT CACYGAMLRH LGRAAVRPAP TDGALQGQLL AQRAGAVRTK VSRLVAAVVL LFAACWGPIQ
LFLVLQALPL GGLAPSKLCA YALKIAHCHM SYSNSALNPL LYAFLGSHFR QAFCRVCPCG PQRQRRPHAS
AHSDRAAPHS VPHSRAAHPV RVRTPEPGNP VVHSPSVQDE HTAPL

FIGURE 5A

		CCA	CAG	TCC	CAG	GAC	GCA	ATC	TGT	GAA	GGC	TGC	CTG	GAG	GAG	GAG	GAG	GGC	GAC	AGG	GCC						
		9				18				27				36				45				54					
Met	Ala	Ala	Glu	Ala	Thr	Leu	Gly	Pro	Asn	Val	Ser	Trp	Trp	Ala	Pro	Ser	Asn	Ala	Ser	Gly	Cys						
ATG	GCC	GCA	GAG	GCG	ACG	TTG	GGT	CCG	AAC	GTG	AGC	TGG	TGG	GCT	CCG	TCC	AAC	GCT	TCG	GGA	TGC						
		69				78				87				96				105				114				123	
Pro	Gly	Cys	Gly	Val	Asn	Ala	Ser	Asp	Gly	Pro	Gly	Ser	Ala	Pro	Arg	Pro	Leu	Asp	Ala	Trp	Leu						
CCG	GGC	TGC	GGT	GTC	AAT	GCC	TCG	GAT	GGC	CCA	GGC	TCC	GCG	CCA	AGG	CCC	CTG	GAT	GCC	TGG	CTG						
		135				144				153				162				171				180				189	
Val	Pro	Leu	Phe	Phe	Ala	Ala	Leu	Met	Leu	Leu	Gly	Leu	Val	Gly	Asn	Ser	Leu	Val	Ile	Phe	Val						
GTG	CCC	CTG	TTT	TTC	GCT	GCC	CTA	ATG	TTG	CTG	GGG	CTA	GTC	GGG	AAC	TCA	CTG	GTC	ATC	TTC	GTT						
		201				210				219				228				237				246				255	
Ile	Cys	Arg	His	Lys	His	Met	Gln	Thr	Val	Thr	Asn	Phe	Tyr	Ile	Ala	Asn	Leu	Ala	Ala	Thr	Asp						
ATC	TGC	CGC	CAC	AAG	CAC	ATG	CAG	ACC	GTC	ACC	AAT	TTC	TAC	ATC	GCT	AAC	CTG	GCG	GCC	ACA	GAT						
		267				276				285				294				303				312				321	
Val	Thr	Phe	Leu	Leu	Cys	Cys	Val	Pro	Phe	Thr	Ala	Leu	Leu	Tyr	Pro	Leu	Pro	Thr	Trp	Val	Leu						
GTC	ACT	TTC	CTT	CTG	TGC	TGC	GTA	CCC	TTC	ACC	GCG	CTC	CTC	TAT	CCG	CTG	CCC	ACC	TGG	GTG	CTG						
		333				342				351				360				369				378				387	
Gly	Asp	Phe	Met	Cys	Lys	Phe	Val	Asn	Tyr	Ile	Gln	Gln	Val	Ser	Val	Gln	Ala	Thr	Cys	Ala	Thr						
GGA	GAC	TTC	ATG	TGC	AAA	TTC	GTC	AAC	TAC	ATC	CAG	CAG	GTC	TCG	GTG	CAA	GCC	ACA	TGT	GCC	ACT						
		399				408				417				426				435				444				453	
Leu	Thr	Ala	Met	Ser	Val	Asp	Arg	Trp	Tyr	Val	Thr	Val	Phe	Pro	Leu	Arg	Ala	Leu	His	Arg	Arg						
TTG	ACA	GCC	ATG	AGT	GTG	GAC	CGC	TGG	TAC	GTG	ACT	GTG	TTC	CCG	CTG	CGT	GCA	CTT	CAC	CGC	CGC						
		465				474				483				492				501				510				519	
Thr	Pro	Arg	Leu	Ala	Leu	Thr	Val	Ser	Leu	Ser	Ile	Trp	Val	Gly	Ser	Ala	Ala	Val	Ser	Ala	Pro						
ACT	CCG	CGC	CTG	GCC	CTG	ACT	GTC	AGC	CTT	AGC	ATC	TGG	GTG	GGT	TCC	GCA	GCT	GTT	TCC	GCC	CCG						
		531				540				549				558				567				576				585	
Val	Leu	Ala	Leu	His	Arg	Leu	Ser	Pro	Gly	Pro	His	Thr	Tyr	Cys	Ser	Glu	Ala	Phe	Pro	Ser	Arg						
GTG	CTG	GCT	CTG	CAC	CGC	CTG	TCG	CCC	GGG	CCT	CAC	ACC	TAC	TGC	AGT	GAG	GCG	TTT	CCC	AGC	CGT						
		597				606				615				624				633				642				651	
Ala	Leu	Glu	Arg	Ala	Phe	Ala	Leu	Tyr	Asn	Leu	Leu	Ala	Leu	Tyr	Leu	Leu	Pro	Leu	Leu	Ala	Thr						
GCC	CTG	GAG	CGC	GCT	TTC	GCG	CTC	TAC	AAC	CTG	CTG	GCC	CTA	TAC	CTG	CTG	CCG	CTG	CTC	GCC	ACC						
		663				672				681				690				699				708				717	

FIGURE 5B

Cys	Ala	Cys	Tyr	Gly	Ala	Met	Leu	Arg	His	Leu	Gly	Arg	Ala	Ala	Val	Arg	Pro	Ala	Pro	Thr	Asp
TGC	GCC	TGC	TAC	GGT	GCC	ATG	CTG	CGC	CAC	CTG	GGC	CGC	GCC	GCT	GTA	CGC	CCC	GCA	CCC	ACT	GAT
	729				738			747			756			765			774			783	
Gly	Ala	Leu	Gln	Gly	Gln	Leu	Leu	Ala	Gln	Arg	Ala	Gly	Ala	Val	Arg	Thr	Lys	Val	Ser	Arg	Leu
GGC	GCC	CTG	CAG	GGG	CAG	CTG	CTA	GCA	CAG	CGC	GCT	GGA	GCA	GTG	CGC	ACC	AAG	GTC	TCC	CGG	CTG
	795				804			813			822			831			840			849	
Val	Ala	Ala	Val	Val	Leu	Leu	Phe	Ala	Ala	Cys	Trp	Gly	Pro	Ile	Gln	Leu	Phe	Leu	Val	Leu	Gln
GTG	GCC	GCT	GTC	GTC	CTG	CTC	TTC	GCC	GCC	TGC	TGG	GGC	CCG	ATC	CAG	CTG	TTC	CTG	GTG	CTT	CAA
	861				870			879			888			897			906			915	
Ala	Leu	Pro	Leu	Gly	Gly	Leu	Ala	Pro	Ser	Lys	Leu	Cys	Ala	Tyr	Ala	Leu	Lys	Ile	Trp	Ala	His
GCC	CTG	CCG	CTC	GGG	GGC	CTG	GCA	CCC	TCG	AAG	CTA	TGC	GCC	TAC	GCG	CTC	AAG	ATC	TGG	GCT	CAC
	927				936			945			954			963			972			981	
Cys	Met	Ser	Tyr	Ser	Asn	Ser	Ala	Leu	Asn	Pro	Leu	Leu	Tyr	Ala	Phe	Leu	Gly	Ser	His	Phe	Arg
TGC	ATG	TCC	TAC	AGC	AAT	TCT	GCG	CTC	AAC	CCG	CTG	CTC	TAT	GCC	TTC	CTG	GGT	TCC	CAC	TTC	AGA
	993				1002			1011			1020			1029			1038			1047	
Gln	Ala	Phe	Cys	Arg	Val	Cys	Pro	Cys	Gly	Pro	Gln	Arg	Gln	Arg	Arg	Pro	His	Ala	Ser	Ala	His
CAG	GCC	TTC	TGC	CGC	GTG	TGC	CCC	TGC	GGC	CCG	CAA	CGC	CAG	CGT	CGG	CCC	CAC	GCG	TCA	GCG	CAC
	1059				1068			1077			1086			1095			1104			1113	
Ser	Asp	Arg	Ala	Ala	Pro	His	Ser	Val	Pro	His	Ser	Arg	Ala	Ala	His	Pro	Val	Arg	Val	Arg	Thr
TCG	GAC	CGA	GCC	GCA	CCC	CAT	AGT	GTG	CCG	CAC	AGC	CGG	GCT	GCG	CAC	CCT	GTC	CGG	GTC	AGG	ACC
	1125				1134			1143			1152			1161			1170			1179	
Pro	Glu	Pro	Gly	Asn	Pro	Val	Val	His	Ser	Pro	Ser	Val	Gln	Asp	Glu	His	Thr	Ala	Pro	Leu	
CCC	GAG	CCT	GGG	AAC	CCT	GTG	GTG	CAC	TCG	CCC	TCT	GTT	CAG	GAT	GAA	CAC	ACT	GCC	CCA	CTC	TGA
	1191				1200			1209			1218			1227			1236			1245	

GCT GCC

FIGURE 6




FIGURE 7A




FIGURE 7B-C





FIGURE 7D




FIGURE 8

0000	0001	0002	0003	0004	0005	0006	0007	0008	0009	0010	0011	0012	0013	0014	0015	0016	0017	0018	0019	0020	0021	0022	0023	0024	0025	0026	0027	0028	0029	0030	0031	0032	0033	0034	0035	0036	0037	0038	0039	0040	0041	0042	0043	0044	0045	0046	0047	0048	0049	0050	0051	0052	0053	0054	0055	0056	0057	0058	0059	0060	0061	0062	0063	0064	0065	0066	0067	0068	0069	0070	0071	0072	0073	0074	0075	0076	0077	0078	0079	0080	0081	0082	0083	0084	0085	0086	0087	0088	0089	0090	0091	0092	0093	0094	0095	0096	0097	0098	0099	0100	0101	0102	0103	0104	0105	0106	0107	0108	0109	0110	0111	0112	0113	0114	0115	0116	0117	0118	0119	0120	0121	0122	0123	0124	0125	0126	0127	0128	0129	0130	0131	0132	0133	0134	0135	0136	0137	0138	0139	0140	0141	0142	0143	0144	0145	0146	0147	0148	0149	0150	0151	0152	0153	0154	0155	0156	0157	0158	0159	0160	0161	0162	0163	0164	0165	0166	0167	0168	0169	0170	0171	0172	0173	0174	0175	0176	0177	0178	0179	0180	0181	0182	0183	0184	0185	0186	0187	0188	0189	0190	0191	0192	0193	0194	0195	0196	0197	0198	0199	0200	0201	0202	0203	0204	0205	0206	0207	0208	0209	0210	0211	0212	0213	0214	0215	0216	0217	0218	0219	0220	0221	0222	0223	0224	0225	0226	0227	0228	0229	0230	0231	0232	0233	0234	0235	0236	0237	0238	0239	0240	0241	0242	0243	0244	0245	0246	0247	0248	0249	0250	0251	0252	0253	0254	0255	0256	0257	0258	0259	0260	0261	0262	0263	0264	0265	0266	0267	0268	0269	0270	0271	0272	0273	0274	0275	0276	0277	0278	0279	0280	0281	0282	0283	0284	0285	0286	0287	0288	0289	0290	0291	0292	0293	0294	0295	0296	0297	0298	0299	0300	0301	0302	0303	0304	0305	0306	0307	0308	0309	0310	0311	0312	0313	0314	0315	0316	0317	0318	0319	0320	0321	0322	0323	0324	0325	0326	0327	0328	0329	0330	0331	0332	0333	0334	0335	0336	0337	0338	0339	0340	0341	0342	0343	0344	0345	0346	0347	0348	0349	0350	0351	0352	0353	0354	0355	0356	0357	0358	0359	0360	0361	0362	0363	0364	0365	0366	0367	0368	0369	0370	0371	0372	0373	0374	0375	0376	0377	0378	0379	0380	0381	0382	0383	0384	0385	0386	0387	0388	0389	0390	0391	0392	0393	0394	0395	0396	0397	0398	0399	0400	0401	0402	0403	0404	0405	0406	0407	0408	0409	0410	0411	0412	0413	0414	0415	0416	0417	0418	0419	0420	0421	0422	0423	0424	0425	0426	0427	0428	0429	0430	0431	0432	0433	0434	0435	0436	0437	0438	0439	0440	0441	0442	0443	0444	0445	0446	0447	0448	0449	0450	0451	0452	0453	0454	0455	0456	0457	0458	0459	0460	0461	0462	0463	0464	0465	0466	0467	0468	0469	0470	0471	0472	0473	0474	0475	0476	0477	0478	0479	0480	0481	0482	0483	0484	0485	0486	0487	0488	0489	0490	0491	0492	0493	0494	0495	0496	0497	0498	0499	0500	0501	0502	0503	0504	0505	0506	0507	0508	0509	0510	0511	0512	0513	0514	0515	0516	0517	0518	0519	0520	0521	0522	0523	0524	0525	0526	0527	0528	0529	0530	0531	0532	0533	0534	0535	0536	0537	0538	0539	0540	0541	0542	0543	0544	0545	0546	0547	0548	0549	0550	0551	0552	0553	0554	0555	0556	0557	0558	0559	0560	0561	0562	0563	0564	0565	0566	0567	0568	0569	0570	0571	0572	0573	0574	0575	0576	0577	0578	0579	0580	0581	0582	0583	0584	0585	0586	0587	0588	0589	0590	0591	0592	0593	0594	0595	0596	0597	0598	0599	0600	0601	0602	0603	0604	0605	0606	0607	0608	0609	0610	0611	0612	0613	0614	0615	0616	0617	0618	0619	0620	0621	0622	0623	0624	0625	0626	0627	0628	0629	0630	0631	0632	0633	0634	0635	0636	0637	0638	0639	0640	0641	0642	0643	0644	0645	0646	0647	0648	0649	0650	0651	0652	0653	0654	0655	0656	0657	0658	0659	0660	0661	0662	0663	0664	0665	0666	0667	0668	0669	0670	0671	0672	0673	0674	0675	0676	0677	0678	0679	0680	0681	0682	0683	0684	0685	0686	0687	0688	0689	0690	0691	0692	0693	0694	0695	0696	0697	0698	0699	0700	0701	0702	0703	0704	0705	0706	0707	0708	0709	0710	0711	0712	0713	0714	0715	0716	0717	0718	0719	0720	0721	0722	0723	0724	0725	0726	0727	0728	0729	0730	0731	0732	0733	0734	0735	0736	0737	0738	0739	0740	0741	0742	0743	0744	0745	0746	0747	0748	0749	0750	0751	0752	0753	0754	0755	0756	0757	0758	0759	0760	0761	0762	0763	0764	0765	0766	0767	0768	0769	0770	0771	0772	0773	0774	0775	0776	0777	0778	0779	0780	0781	0782	0783	0784	0785	0786	0787	0788	0789	0790	0791	0792	0793	0794	0795	0796	0797	0798	0799	0800	0801	0802	0803	0804	0805	0806	0807	0808	0809	0810	0811	0812	0813	0814	0815	0816	0817	0818	0819	0820	0821	0822	0823	0824	0825	0826	0827	0828	0829	0830	0831	0832	0833	0834	0835	0836	0837	0838	0839	0840	0841	0842	0843	0844	0845	0846	0847	0848	0849	0850	0851	0852	0853	0854	0855	0856	0857	0858	0859	0860	0861	0862	0863	0864	0865	0866	0867	0868	0869	0870	0871	0872	0873	0874	0875	0876	0877	0878	0879	0880	0881	0882	0883	0884	0885	0886	0887	0888	0889	0890	0891	0892	0893	0894	0895	0896	0897	0898	0899	0900	0901	0902	0903	0904	0905	0906	0907	0908	0909	0910	0911	0912	0913	0914	0915	0916	0917	0918	0919	0920	0921	0922	0923	0924	0925	0926	0927	0928	0929	0930	0931	0932	0933	0934	0935	0936	0937	0938	0939	0940	0941	0942	0943	0944	0945	0946	0947	0948	0949	0950	0951	0952	0953	0954	0955	0956	0957	0958	0959	0960	0961	0962	0963	0964	0965	0966	0967	0968	0969	0970	0971	0972	0973	0974	0975	0976	0977	0978	0979	0980	0981	0982	0983	0984	0985	0986	0987	0988	0989	0990	0991	0992	0993	0994	0995	0996	0997	0998	0999	1000	1001	1002	1003	1004	1005	1006	1007	1008	1009	1010	1011	1012	1013	1014	1015	1016	1017	1018	1019	1020	1021	1022	1023	1024	1025	1026	1027	1028	1029	1030	1031	1032	1033	1034	1035	1036	1037	1038	1039	1040	1041	1042	1043	1044	1045	1046	1047	1048	1049	1050	1051	1052	1053	1054	1055	1056	1057	1058	1059	1060	1061	1062	1063	1064	1065	1066	1067	1068	1069	1070	1071	1072	1073	1074	1075	1076	1077	1078	1079	1080	1081	1082	1083	1084	1085	1086	1087	1088	1089	1090	1091	1092	1093	1094	1095	1096	1097	1098	1099	1100	1101	1102	1103	1104	1105	1106	1107	1108	1109	1110	1111	1112	1113	1114	1115	1116	1117	1118	1119	1120	1121	1122	1123	1124	1125	1126	1127	1128	1129	1130	1131	1132	1133	1134	1135	1136	1137	1138	1139	1140	1141	1142	1143	1144	1145	1146	1147	1148	1149	1150	1151	1152	1153	1154	1155	1156	1157	1158	1159	1160	1161	1162	1163	1164	1165	1166	1167	1168	1169	1170	1171	1172	1173	1174	1175	1176	1177	1178	1179	1180	1181	1182	1183	1184	1185	1186	1187	1188	1189	1190	1191	1192	1193	1194	1195	1196	1197	1198	1199	1200	1201	1202	1203	1204	1205	1206	1207	1208	1209	1210	1211	1212	1213	1214	1215	1216	1217	1218	1219	1220	1221	1222	1223	1224	1225	1226	1227	1228	1229	1230	1231	1232	1233	1234	1235	1236	1237	1238	1239	1240	1241	1242	1243	1244	1245	1246	1247	1248	1249	1250	1251	1252	1253	1254	1255	1256	1257	1258	1259	1260	1261	1262	1263	1264	1265	1266	1267	1268	1269	1270	1271	1272	1273	1274	1275	1276	1277	1278	1279	1280	1281	1282	1283	1284	1285	1286	1287	1288	1289	1290	1291	1292	1293	1294	1295	1296	1297	1298	1299	1300	1301	1302	1303	1304	1305	1306	1307	1308	1309	1310	1311	1312	1313	1314	1315	1316	1317	1318	1319	1320	1321	1322	1323	1324	1325	1326	1327	1328	1329	1330	1331	1332	1333	1334	1335	1336	1337	1338	1339	1340	1341	1342	1343	1344	1345	1346	1347	1348	1349	1350	1351
------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------

	10	20	30	40	50	60
rat	MAAEATLGPVNSWWAPSNASGCPGCGVNASDGPGSAPRPLDAWLVPLFFAALMLLGLVGN					
human	MHTVATSGPNASWGAPANASGCPGCGANASDGPVPSRAVDWLVLFFAALMLLGLVGN					
	10	20	30	40	50	60
	70	80	90	100	110	120
rat	SLVIFVICRHKHMQTVTNFYIANLAATDVTFLLCVPFTALLYPLPTWVLGDFMCKFVNY					
human	SLVIYVICRHKPMRTVTNFYIANLAATDVTFLLCVPFTALLYPLPGWVLGDFMCKFVNY					
	70	80	90	100	110	120
	130	140	150	160	170	180
rat	IQQVSVQATCATLTAMSVDRWYVTVFPLRALHRRTPRLALTVSLSIWVGSAAVSAPVLAL					
human	IQQVSVQATCATLTAMSVDRWYVTVFPLRALHRRTPRLALAVSLSIWVGSAAVSAPVLAL					
	130	140	150	160	170	180
	190	200	210	220	230	240
rat	HRLSPGPHTYCSEAFPSRALERAFALYNLLALYLLPLLATCACYGAMLRHLGRAAVRPAP					
human	HRLSPGPRAYCSEAFPSRALERAFALYNLLALYLLPLLATCACYAAMLRHLGRVAVRPAP					
	190	200	210	220	230	240
	250	260	270	280	290	
rat	TDGALQGQLLAQAGAVRTKVSRLVAAVVLLFAACWGPIQLFLVLQAL-PLGGLAPSKLC					
human	ADSALQGQVLAERAGAVRAKVSRLVAAVVLLFAACWGPIQLFLVLQALGPAGSWHPRSYA					
	250	260	270	280	290	300
	300	310	320	330	340	350
rat	AYALKIWAHCMSYSNSALNPLLYAFLGSHFRQAFRCRVCPGPGQRQRRPHASAHSDRAAPH					
human	AYALKTWAHCMSYSNSALNPLLYAFLGSHFRQAFRRVCPCAPRRPRRRPGPSDPAAPH					
	310	320	330	340	350	360
	360	370	380	390		
rat	SVPHSRAAHPVRVRTPEPGNP--VVHSPSVQDEHTAPL					
human	AELLRLGSHPAPARAQKPGSSGLAARGLCVLGEDNAPL					
	370	380	390			

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/04416

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C12N 5/10, 15/00, 15/09, 15/11, 15/12, 15/63

US CL : 435/320.1, 325; 536/23.5

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/320.1, 325; 536/23.5

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X - A	WO 98/03548 A1 (ASTRA PHARMA, INC.) 29 January 1998 (29.01.98), especially pages 8-9.	3 ----- 1-2, 4-5
X, P	LEE et al. "Discovery of a receptor related to the galanin receptors," FEBS Letters. 05 March 1999. Vol. 446, No.1, pages 103-107, especially page 103 and figures 1-3.	1-5

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

Z

document member of the same patent family

Date of the actual completion of the international search

15 AUGUST 2000

Date of mailing of the international search report

07 SEP 2000

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

MICHAEL PAK

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/04416

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-5

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/04416

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

BRS, STN, MEDLINE, GENBANK, PIR, EMBL, GENESEQ, EST

search terms: g-protein receptor, galanin receptor, cDNA, GPCR, GPR54

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claim(s) 1-5, drawn to an isolated DNA, expression vector, and recombinant host cell.

Group II, claim(s) 6-9, drawn to an isolated polypeptide.

Group III, claim(s) 10-11, drawn to a method of determining whether a substance is an agonist or antagonist by binding.

Group IV, claim(s) 12, drawn to a method of determining whether a substance is an agonist or antagonist by functional response.

Group V, claim(s) 13, drawn to an antibody.

and it considers that the International Application does not comply with the requirements of unity of invention (Rules 13.1, 13.2 and 13.3) for the reasons indicated below:

The inventions listed as Groups I-V do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features because the product of claim 3 is anticipated by ASTRA PHARMA INC. (WO 98/03548, 29 January 1998, pages 7-8) and thus, does not share a special technical feature with any other group.

The special technical feature of Group I is a DNA, an expression vector, and a host cell. Pursuant to 37 CFR 1.475(d), these claims are considered by the ISA/US to constitute the main invention, and none of the related groups II-V correspond to the main invention.

The products of Group II and V do not share the same or corresponding special technical feature with Group I, because they are drawn to products having materially different structures and functions, and each defines a separate invention over the art.

The methods of Groups III and IV, do not share the same or corresponding special technical feature with Group I, because the methods have materially different process steps and are practiced for materially different purposes, and each defines a separate invention over the art.

Since Groups I-V do not share a special technical feature, unity of invention is lacking.

PATENT COOPERATION TREATY

PCT

RECD 04 MAY 2001

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

PCT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 20397-PCT	FOR FURTHER ACTION	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
International application No. PCT/US00/04416	International filing date (day/month/year) 22 FEBRUARY 2000	Priority date (day/month/year) 24 FEBRUARY 1999
International Patent Classification (IPC) or national classification and IPC IPC(7): C12N 5/10, 15/00, 15/09, 15/11, 15/12, 15/63 and US Cl.: 435/320.1, 325; 536/23.5		
Applicant MERCK & CO., INC.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of 5 sheets.

☐ This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority. (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 0 sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☒ Non-establishment of report with regard to novelty, inventive step or industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☐ Certain observations on the international application

Date of submission of the demand 25 SEPTEMBER 2000	Date of completion of this report 01 APRIL 2001
Name and mailing address of the IPEA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer MICHAEL PAK TERRY J. DEY PARALEGAL SPECIALIST TECHNOLOGY CENTER 1600 Telephone No. (703) 308-0196

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US00/04416

I. Basis of the report**1. With regard to the elements of the international application: ***☒ the international application as originally filed☒ the description:pages 1-33, as originally filedpages NONE, filed with the demandpages NONE, filed with the letter of _____☒ the claims:pages 34-36, as originally filedpages NONE, as amended (together with any statement) under Article 19pages NONE, filed with the demandpages NONE, filed with the letter of _____☒ the drawings:pages 1-15, as originally filedpages NONE, filed with the demandpages NONE, filed with the letter of _____☒ the sequence listing part of the description:pages 1-8, as originally filedpages NONE, filed with the demandpages NONE, filed with the letter of _____**2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.**

These elements were available or furnished to this Authority in the following language _____ which is:

☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).☐ the language of publication of the international application (under Rule 48.3(b)).☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).**3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:**☐ contained in the international application in printed form.☐ filed together with the international application in computer readable form.☒ furnished subsequently to this Authority in written form.☒ furnished subsequently to this Authority in computer readable form.☒ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.☒ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.**4. ☒ The amendments have resulted in the cancellation of:**☒ the description, pages NONE☒ the claims, Nos. NONE☒ the drawings, sheets/fig NONE**5. ☐ This report has been drawn as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).****

* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

**Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.
PCT/US00/04416

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be industrially applicable have not been and will not be examined in respect of:

☐ the entire international application.

☒ claims Nos. 6-13

because:

☐ the said international application, or the said claim Nos. _ relate to the following subject matter which does not require international preliminary examination (*specify*).

☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. _ are so unclear that no meaningful opinion could be formed (*specify*).

☐ the claims, or said claims Nos. _ are so inadequately supported by the description that no meaningful opinion could be formed.

☒ no international search report has been established for said claims Nos. 6-13.

2. A meaningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

☐ the written form has not been furnished or does not comply with the standard.

☐ the computer readable form has not been furnished or does not comply with the standard.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US00/04416

Supplemental Box

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: Boxes I - VIII

Sheet 10

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/04416**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(7) : C12N 5/10, 15/00, 15/09, 15/11, 15/12, 15/63

US CL : 435/320.1, 325; 536/23.5

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/320.1, 325; 536/23.5

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X - A	WO 98/03548 A1 (ASTRA PHARMA, INC.) 29 January 1998 (29.01.98), especially pages 8-9.	3 ----- 1-2, 4-5
X, P	LEE et al. "Discovery of a receptor related to the galanin receptors," FEBS Letters. 05 March 1999. Vol. 446, No.1, pages 103-107, especially page 103 and figures 1-3.	1-5

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* "A"	Special categories of cited documents: document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E"	earlier document published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O"	document referring to an oral disclosure, use, exhibition or other means	"G" document member of the same patent family
"P"	document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

15 AUGUST 2000

Date of mailing of the international search report

07 SEP 2000

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

MICHAEL PAK

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/04416

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-5

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/04416

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

BRS, STN, MEDLINE, GENBANK, PIR, EMBL, GENESEQ, EST

search terms: g-protein receptor, galanin receptor, cDNA, GPCR, GPR54

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claim(s) 1-5, drawn to an isolated DNA, expression vector, and recombinant host cell.

Group II, claim(s) 6-9, drawn to an isolated polypeptide.

Group III, claim(s) 10-11, drawn to a method of determining whether a substance is an agonist or antagonist by binding.

Group IV, claim(s) 12, drawn to a method of determining whether a substance is an agonist or antagonist by functional response.

Group V, claim(s) 13, drawn to an antibody.

and it considers that the International Application does not comply with the requirements of unity of invention (Rules 13.1, 13.2 and 13.3) for the reasons indicated below:

The inventions listed as Groups I-V do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features because the product of claim 3 is anticipated by ASTRA PHARMA INC. (WO 98/03548, 29 January 1998, pages 7-8) and thus, does not share a special technical feature with any other group.

The special technical feature of Group I is a DNA, an expression vector, and a host cell. Pursuant to 37 CFR 1.475(d), these claims are considered by the ISA/US to constitute the main invention, and none of the related groups II-V correspond to the main invention.

The products of Group II and V do not share the same or corresponding special technical feature with Group I, because they are drawn to products having materially different structures and functions, and each defines a separate invention over the art.

The methods of Groups III and IV, do not share the same or corresponding special technical feature with Group I, because the methods have materially different process steps and are practiced for materially different purposes, and each defines a separate invention over the art.

Since Groups I-V do not share a special technical feature, unity of invention is lacking.